

Curriculum Vitae
Dr. Anne W. M. LEE

Medical Professional Qualifications & Education

<u>Primary Degree</u>	<u>Year</u>
MB BS (HK)	1976
 <u>Postgraduate Degrees</u>	
MD (HK)	2008
FHKAM (HK)	1993
FHKCR (HK)	1992
FRCR	1983
 <u>Degree-Granting Education</u>	
Medical Faculty, The University of Hong Kong	1971-1976
 <u>Postgraduate Training in Overseas Centers</u>	
Princess Margaret Hospital, Canada	1988
Stanford University, U. S. A.	1988
Royal Marsden Hospital, U. K.	1981-1982
 <u>National Qualification</u>	
腫瘤放射治療學主任醫師 (正高級別)	2021

Academic Appointments

<u>Shenzhen-Hong Kong Medical Specialist Training Centre (SZ-HK MSTC)</u>	
深港醫學專科培訓中心	
Vice President 副主席	since 2020
Executive Committee Member 執行委員會委員	since 2020
 <u>Shenzhen Hospital Accreditation Research Center (SHARC)</u>	
深圳市衛健醫院評審評價研究中心	
Director 主任	since 2020
 <u>Tsinghua Shenzhen International Graduate School</u>	
External Supervisor	2020-2023
 <u>The University of Hong Kong</u>	
Department of Clinical Oncology, Li Ka Shing Faculty of Medicine	
Alice Ho Miu Ling Nethersole Charity Foundation Professorship in Holistic Cancer Care	since 2017
Clinical Professor	since 2015

Head of Department	2015-2021
Honorary Clinical Professor	2009-2015
Honorary Clinical Associate Professor	2000-2009
<u>Peking Union Medical College Hospital</u>	
Honorary Professor	since 2016
<u>The Chinese University of Hong Kong</u>	
Department of Clinical Oncology, Faculty of Medicine	
Adjunct Associate Professor	1999-2005
<u>Clinical and Administrative Appointments</u>	
<u>The University of Hong Kong - Shenzhen Hospital</u>	
Deputy Hospital Chief Executive (Education & Training)	since 2019
Deputy Hospital Chief Executive (Clinical Service)	since 2017
Chief of Service, Center of Clinical Oncology	since 2012
<u>Department of Clinical Oncology, Queen Mary Hospital, Hong Kong</u>	
Deputy Chief of Service of Clinical Oncology	since 2017
Consultant (Honorary)	since 2015
<u>Hong Kong Sanatorium & Hospital</u>	
Consultant (Honorary)	2020-2022
<u>Gleneagles Hong Kong Hospital</u>	
Chair of Specialty for Oncology	2015-2018
Consultant (Honorary)	since 2017
<u>Hospital Authority Hong Kong East Cluster</u>	
Consultant (Healthcare management) for Training Center (Honorary)	2013-2018
Cluster Chief of Service of Clinical Oncology	2005-2011
Coordinator of Clinical Oncology	2001-2005
<u>Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong</u>	
Consultant (Honorary)	2012-2018
Consultant (Part-time)	2012
Chief of Service	1994-2012
Consultant (full-time)	1993-2012
<u>Nam Long Hospital</u>	
Honorary Consultant (Clinical Oncology)	1998-1999
<u>Institute of Radiology and Oncology, Queen Elizabeth Hospital, Hong Kong</u>	

Consultant	1991-1993
Senior Medical & Health Officer	1985-1991
Medical & Health Officer	1977-1985

Other Professional Qualifications

Traditional Chinese Medicine

Certificate in Chinese Medicine for Hospital Authority Medical and Healthcare Professionals (by The University of Hong Kong)	2011
--	------

International Standard Organization (ISO) Quality Management System

QMS 2008 Auditor (by IRCA)	2009-2012
QMS 2000 Auditor (by IRCA)	2007-2009
ISO 9001: 2000 Auditor/Lead Auditor Certificate (by BSI)	2001

Awards & Honors

Professional Achievements

First Prize of Technology Award by Fujian Anti-Cancer Association 科技進步一等獎 – 項目「鼻咽癌精準診療體系的建立與應用研究」 - 福建省抗癌協會授予	2021
Honorary Fellow by American College of Radiology	2019
First Prize of Science and Technology Award - ‘Research on staging and precision radiotherapy for nasopharyngeal cancer’ by Fujian Government 福建省科學技術獎一等獎 – 項目「基於 MRI 的鼻咽癌臨床分期和精確放療的應用研究」 - 福建省人民政府授予	2018
Wharton Lecturer by The University of Toronto, Princess Margaret Hospital, Canada	2015
Honorary Membership by Radiological Society of North America	2013
Honorary Membership by European Society of Therapeutic Radiology and Oncology	2012
Gilbert H. Fletcher Distinguished Professor Lecturer by The University of Texas, M.D. Anderson Cancer Center, U.S.A.	2009
Sir Patrick Manson Gold Medal	2008

by The University Hong Kong

Clinical/Administrative Achievements

Third Prize of Hospital Management Innovation Award - Project "Development and clinical application of a new model for cancer clinical pathway" by Guangdong Provincial Hospital Association 醫院管理創新獎三等獎 – 項目「腫瘤臨床路徑的規劃及其應用與管理系統之研發」 - 廣東省醫院協會授予	2020
Excellent Medical Personnel of Shenzhen Municipality 2020 by Shenzhen Municipal Health Commission 2020年深圳市優秀醫師 - 深圳市衛生健康委員會授予	2020
Star of the Year by China Humanistic Hospital Brand Summit 2020 of Chinese Association For Life Care 風尚人物 - 中國生命關愛協會“2020中國醫院人文品牌峰會”授予	2020
Public Satisfaction—Medical Personnel of 2019 for Medical Service Improvement by Health News, Bureau of Medical Administration, National Health Commission 2019年度改善醫療服務群眾滿意的醫務工作者 - 國家衛生健康委員會醫政醫管局健康報社授予	2019
Outstanding Contribution—Medical Personnel of 2019 for Medical Service Improvement by Health News, Bureau of Medical Administration, National Health Commission 2019年度改善醫療服務突出貢獻工作者 - 國家衛生健康委員會醫政醫管局健康報社授予	2019
Good Doctor in Shenzhen by Health and Family Planning commission of Shenzhen Municipality 深圳好醫生 - 深圳市衛生和計劃生育委員會授予	2018
Outstanding Team Award by Hospital Authority Member of Committee on Public Private Interface Leader of Quality Management Team	2004 2003

Reviewer for Academic/Professional Institutes

<u>The University of Hong Kong</u> Life Sciences Panel of the University Selection and Promotion Committee Member	2020-2022
---	-----------

Hong Kong Polytechnic University

Member of Advisory Committee on Radiography	1998
External assessor for conferment of title of professor	1998
Expert Adviser for Research Committee	1995

Records in Research / Project Grants & Role in Large-Scale Research ProjectsStrategic Public Policy Research (SPPR) Funding Scheme

Promoting HK Residents' Cross-border Healthcare Utilization and Cross-border Mobility in the Greater Bay Area: Recent Priorities and Long-term Policy Framework	HK\$3,910,052.90
Co-Investigator	2022-2025

Partnership Research Programme by Innovation and Technology Fund

Precision Oncology Programme for Non-Small-Cell-Lung Cancer Project Coordinator	HK\$ 50,019,500 2021-2024
---	------------------------------

National Natural Science Foundation of China (NSFC/RGC)

Organizational Reform and Innovation in Management of Public Hospitals basing on integration of systems through Shenzhen-Hong Kong Collaboration 組織變革與創新下的公立醫院制度融合：基於深港合作的案例與實證研究 Project Code: N_HKU771/20(Hong Kong); 7201101045(Mainland)	RMB 1,000,000 and HK\$1,171,828
Co-investigator	2021-2024

Health and Medical Research Fund

A Web-based Intervention for Promoting Physical Activity among Post-treatment Cancer Survivors (WExercise) Using the Multi-process Action Control Framework: Development, Usability, and Efficacy (Ref: 06200067)	HK\$995,909
Co-investigator	2021-2023

Advanced Energy Science and Technology Guangdong Laboratory,
Guangdong province and Huizhou city, governed by Science and
Technology Agency of Guangdong province
先進能源科學與技術廣東省實驗室

Radioisotopes in cancer diagnosis and treatment: Study of biomimetic nanomaterials for drug delivery 醫用核素腫瘤診治一體化研究團隊	RMB 20,000,000
Co-Investigator	2020-2023

Innovative and Technology Commission Health@InnoHK

Laboratory for Synthetic Chemistry and Chemical Biology	HK\$ 502,300,000
---	------------------

Co-Project Coordinator	2020-2025
<u>National Natural Science Foundation of China "COVID-19"</u>	
Integrated and coordinated governance mechanism between public health system and medical insurance system 公共衛生體系與醫療服務和醫療保障體系的融合協同機制	RMB 500,000
Project Code: 72042002	
Co-investigator	2020-2021
<u>Health Commission of Shenzhen Municipality</u>	RMB 12,000,000
<u>深圳市衛生健康委員</u>	
Shenzhen Shenzhen Sanming project 深圳医疗卫生三名工程	2017-2021
Leader of introductory department 引进科室带头人	
<u>Area of Excellence Scheme by University Grants Committee</u>	
Center for Nasopharyngeal Cancer Research Projects	HK\$ 1,880,000
Co-PI - Leader of Research Committee on Clinical Sciences	2010 -2018
<u>International Atomic Energy Agency</u>	
A Situation Analysis of National Radiotherapy resources and Patterns of Care for Patients with Nasopharyngeal Carcinoma in Low-Middle Income Countries: Can Enhancing the Quality of Radiotherapy Planning Improve Outcomes - Coordinated Research Project (CRP) (325-E3-TM-47712)	
Principal Investigator	2016
<u>University Research Committee - Seed Funding for Basic Research</u>	
Prognostic and predictive tissue biomarkers in locally advanced nasopharyngeal carcinoma treated with radiotherapy alone or in conjunction with chemoradiotherapy: pooled analysis of data from the NPC-9901, NPC-9902 and NPC-0501 studies.	HK\$ 300,000
Principal Investigator	2016
<u>Shenzhen Science and Technology Project 深圳市科技計劃</u>	
Research on design, application and monitoring of clinical pathway 腫瘤臨床路徑的規劃及其應用與管理系統之研發	RMB 100,000
Principal Investigator	2014
<u>Hong Kong Nasopharyngeal Cancer Study Group – Clinical Trials NPC-9901, NPC-9902, and NPC-0501</u>	
Hong Kong Hospital Authority	HK\$ 1,000,000
Hong Kong Anti-Cancer Society	HK\$ 650,000
Hong Kong Nasopharyngeal Cancer Study Group	HK\$ 600,000

Ho Hung Chiu Medical Foundation Limited	HK\$ 324,180
Hong Kong Cancer Fund	HK\$ 317,040

- Randomized Trial comparing the Therapeutic Gain by Induction-Concurrent Chemoradiation vs. Concurrent-Adjuvant Chemoradiation and the Efficacy of Capecitabine vs. 5-Fluorouracil for Advanced Nasopharyngeal Carcinoma (NPC-0501 Trial)
Principal Investigator 2006
- Prospective Randomized Study on Therapeutic Gain Achieved by Addition of Chemotherapy for T1-4N2-3M0 Nasopharyngeal Carcinoma (NPC-9901 Trial)
Principal Investigator 1999
- Prospective Randomized Study on Therapeutic Gain Achieved by Chemoradiation and/or Accelerated Radiation for T3-4N0-1M0 Nasopharyngeal Carcinoma (NPC-9902 Trial)
Principal Investigator 1999

Hospital Governance & Leading Role in Hospital Services Committee

Consortium on Harmonization of Institutional Requirements for Clinical Research (CHAIR)

Member of Joint Scientific Committee (JSC) for Phase 1 Clinical Trials	2014-2023
--	-----------

Hong Kong Hospital Authority

External Advisor, Li Ka Shing Foundation “Heart of Gold” Hospice Service Program – Project Management Committee	2014
---	------

Chairman of Coordinating Committee (Clinical Oncology)	2010-2012
--	-----------

Member of Drug Advisory Committee	2008-2012
-----------------------------------	-----------

Member of Hospital Authority Research Ethics Committee	2005-2007
--	-----------

Specialist Coordinator for e-Knowledge Gateway	2000-2011
--	-----------

St. Paul’s Hospital

Member of Radiology Advisory Committee	2011-2013
--	-----------

Hong Kong East Cluster

Chairman of Community Service Committee (Cancer)	2006-2012
--	-----------

Chairman of Cancer Services Coordinating Committee	2005-2012
--	-----------

Deputy Chairman of Ethics Committee of Hong Kong East Cluster	2003-2007
---	-----------

Chairman of Hospital Ethics Committee of Pamela Youde Nethersole Eastern Hospital	2000-2003
---	-----------

Hong Kong Anti-Cancer Society Jockey Club Cancer Rehabilitation Center

Vice Chairman of Hospital Governing Committee	2008-2010
---	-----------

Chairman of Clinical Research Ethics Committee	2008-2010
Bradbury Hospice Member of Hospital Governing Committee	1995-2005
Nam Long Hospital Member of Hospital Governing Committee	2002-2004

Appointments by the Hong Kong Special Administrative Region

Panel of Assessors for Hong Kong Medical Council	2011-2012
Member of Public Affairs Forum	2011
Member of Radiological Protection Advisory Group	2007-2013
Member of Radiation Board	2005-2011
Member of Government's Cancer Coordinating Committee	2001-2012

Non-Government Community Services

Local

Hong Kong Anti-Cancer Society	
Chairman of Cancer Education, Prevention and Early Detection Committee	since 2015
Vice-Chairman	since 2008
Chairman of Cancer Research Subcommittee	2004-2012
Chairman of Cancer Education Subcommittee	1994-2003
Member of Executive Council	since 1994
Hong Kong Council on Smoking and Health	
Co-opted member of Legislative Committee	2011-2020

Overseas

Associacao Dos Amigos Da Caridade de Macau Honorary Consultant	1996-2002
---	-----------

Expert Member / Coordinator for International Professional Organizations

European Society of Medical Oncology Honorary Advisor for Hong Kong Women for Oncology	2020
Faculty Member on Nasopharyngeal Cancer	2006
International Head and Neck Scientific Group Member	since 2018

EORTC Protocol Review Committee (PRC) External reviewer	2017
Union of International Cancer Control UICC Board of Directors	since 2016
Coordinator of UICC TNM Global Advisory Group	since 2013
UICC TNM Expert Advisory Panel on Head and Neck Cancers	2001
American Joint Committee on Cancer Expert Panel on Head and Neck Cancers	2014
Chairman of Subcommittee on Nasopharyngeal Cancer	2014
Expert Panel on Skin Cancers	2014
American Society of Therapeutic Radiology and Oncology Consultant to the International Relations Committee	2000-2007
ASTRO Leadership Team	2001
Expert Member for WHO Classification of Head and Neck Tumours	2003

Leading Role in Local / National Professional Organizations

National

Clinical Research Quality Control Center of Guangdong Province 廣東省臨床研究品質控制中心 Deputy Chairman 執行副主任執行副主任	2022-2025
Precision Treatment of Nasopharyngeal Cancer Sub-Committee, under the Clinical Medicine Committee of Guangdong Province 廣東省臨床醫學學會鼻咽癌精準治療專業委員會 Honorary Chairman 名譽主任委員	2020-2025
National Cancer Staging Committee of China Vice Chairman of National Committee	since 2013
Chairman of Hong Kong Regional TNM Cancer Staging Subcommittee	2010-2013
Co-Chairman of National Preparatory Committee	2010-2013
Pan-Pearl River Delta Radiation Oncology Conference Committee Committee Member	since 2006
Macau Oncology Association Honorary Consultant	2006

Local

Hong Kong College of Radiologists	
Vice President	2009-2021
Council member	2008
Member of the Subcommittee on Continuous Medical Education	1994-1996
Member of the Scientific and Education Committee	1992-1994
Secretary of the Membership Committee	1991-1994
Hong Kong Nasopharyngeal Cancer Study Group (Limited)	
Chairman	since 2018
	2005-2007
Council member	2007-2011
Founding Vice Chairman	1999-2004
Hong Kong Head and Neck Society (Limited)	
President	1996, 2003
President Elect	1995, 2002
Treasurer	1992-1994
Ho Hung Chiu Medical Education Foundation Limited	
Council Member	since 1997
Hong Kong Society of Clinical Oncology	
Council member	since 1991

Editor for Professional Journals

International Journals

Radiotherapy & Oncology	
Senior Editor (Clinical)	since 2021
Board of Editors	2010-2020
Journal of Clinical Oncology	
Board of Editors	2013
Clinical Oncology	
Board of Editors	2011
Oral Oncology	
Associate Editor for Translational Research	2011-2021
International Journal of Radiation Oncology, Biology and Physics	
Board of Editors	1998-2000
American Journal of Clinical Oncology	

Board of Editors

1997

National Journals

Chinese Clinical Oncology
Board of Editors

since 2016

Local Journals

MIMS Oncology Hong Kong
Honorary Editorial Advisory Board member

since 2019

The Journal of the Hong Kong College of Radiologists
Board of Editors

1998-2000

MD Thesis

Therapeutic Benefits of Concurrent Chemoradiotherapy for Advanced Nasopharyngeal Carcinoma, The University of Hong Kong, 2008

Publications

Book

1. **Lee AWM**, Lung ML, Ng WT (Eds). Nasopharyngeal Carcinoma: From Etiology to Clinical Practice. 1st Edition. Elsevier, 2019.
2. Wittekind C, Brierley JD, **Lee AMW**, Eycken E van. TNM Supplement: A Commentary on Uniform Use, 5th Edition. Wiley-Blackwell, 2019.
3. Brierley JD, Gospodarowicz MK, Wittekind C, O’Sullivan B, Manson M, Asamura H, **Lee A**, Eycken EV, Denny L, Amin MB, Gupta S (Eds). TNM Classification of MALIGNANT TUMOURS. 8th Edition. WILEY Blackwell, 2017.
4. Lu JJ, Cooper JS, **Lee AWM** (Eds). Nasopharyngeal Cancer. Medical Radiology - Radiation Oncology. Verlag Berlin Heidelberg: Springer, 2010.

Chapters

1. Chan JKC, Seethala R, **Lee AWM**. Nasopharyngeal carcinoma. In: WHO Classification of tumours: Paediatric tumours, Chapter 13 Head and neck tumours, Malignant tumours, 2022.
2. Lee VHF, **Lee AWM**. Principle of Cancer Radiotherapy. In: Radiotherapy of Liver Cancer. Springer, Chapter 1, pp 3-14, 2021.
3. Ng WT, Kuk SY, Sze HCK, O’Sullivan, **Lee AWM**. Diagnosis and Staging of Nasopharyngeal Cancer. In: Nasopharyngeal Cancer: A Practical Guide on Diagnosis and Treatment. Springer, Chapter 1, pp 2-21, 2021.
4. **Lee AWM**, Zong JF, Pan JJ, Choi HCW, Sze HCK. Staging of Nasopharyngeal Carcinoma based on 8th Edition of the AJCC/UICC Staging System. In: Nasopharyngeal Carcinoma: From Etiology to Clinical Practice. 1st Edition. Lee AWM, Lung ML, Ng WT (Eds). Elsevier, Chapter 9, pp 179-203, 2019.
5. Lee VHF, Lam KO, **Lee AWM**. Standard of Care for Nasopharyngeal Carcinoma (2018-2020). In: Nasopharyngeal Carcinoma: From Etiology to Clinical Practice. 1st Edition. Lee AWM, Lung ML, Ng WT (Eds). Elsevier, Chapter 10, pp 205-238, 2019.
6. Ng WT, Chan OSH, Sze HCK, Lam KO, **Lee AWM**., Nasopharyngeal Carcinoma, Head and Neck Cancer: Evidence-based Treatment. 2018.
7. Lee VHF, Chang ATY, Ng WT and **Lee AWM**. Evidenced-Based Management of Nasopharyngeal Cancers in the Modern Era. Chemoradiotherapy: Concurrent Uses, Efficacy and Impact on Prognosis, 2017.
8. **Lee AWM**, Lydiatt WM, Colevas D, Glastonbury CM, Le QTX, O’Sullivan B, Weber RS and Shah JP. Nasopharynx. In: AJCC Cancer Staging Manual. 8th Edition. Springer, pp103-111, 2017.

9. Ng WT, Ngan RKC, Chan OSH, Sze HCK, Chan JYW, **Lee AWM**. Management of nasopharyngeal carcinoma. In: Head and Neck Cancer: Multimodality Management. 2nd edition. J. Bernier (Ed). Springer, pp 445-473, 2015.
10. **Lee AWM,*** Ng WT, Le QT, Chan ATC, Chan JYW, Sze HCK. Nasopharynx. In: The UICC Manual of Clinical Oncology. 9th edition. O’Sullivan B (ed). Wiley Blackwell, pp 512-523, 2015.
11. Sze HCK, Lam KO, **Lee AWM**. Early stage nasopharyngeal carcinoma. In: Nasopharyngeal Carcinoma: Management Strategies. S Yom, J Wee (Eds). Future Medicine Ltd, London, pp 55-74, 2014.
12. **Lee AWM,*** Ng WT, Yau TK, Law SCK, Wei WI. Management of the nasopharyngeal carcinomas. In: Head and Neck Cancer: Multimodality Management. 1st edition. J. Bernier (Ed). Springer, pp 381-400, 2011.
13. **Lee AWM.*** Neoadjuvant chemotherapy: Trials and conclusions. In Nasopharyngeal Cancer. Medical Radiology - Radiation Oncology, Lu JJ, Cooper JS, **Lee AWM** (Eds). Verlag Berlin Heidelberg: Springer, pp 183-192, 2010.
14. **Lee AWM,*** Yeung MWR, Ng WT. Nasopharynx. In: Functional Preservation and Quality of Life in Head and Neck Radiotherapy PM Harari, NP Connor, C Grau. (Eds). Verlag Berlin Heidelberg: Springer, pp 57-73, 2009.
15. **Lee AWM,*** Perez CA, Law CK, Chua D, Wei W, Chong VFH. Nasopharynx. In: Principles and Practice of Radiation Oncology. EC Halperin, C Perez, LW Brady (Eds), 5th edition. Philadelphia: Lippincott Williams & Wilkins, pp 820-857, 2008.
16. Chan JKC, Bray F, McCarron P, Foo W, **Lee AWM**, Yip T, Kuo TT. Nasopharyngeal carcinoma. In: Pathology & Genetics of Head and Neck Tumours. World Health Organization Classification of Tumours, Lyon: IARC Press, pp 85-97, 2005.
17. **Lee AWM.*** Complications of radiation therapy. In: Nasopharyngeal Carcinoma. CA Van Hasselt, A Gibb (Eds), 2nd edition. Hong Kong: Chinese University Press, pp 255-276, 1999.
18. O’Sullivan B, Irish J, Siu L, **Lee AWM**. Head and neck cancer. In: Manual of Clinical Oncology. RE Pollock (Ed), 7th edition. International Union against Cancer. New York: Wiley-Liss, Inc., pp 341-358, 1999.
19. **Lee AWM,*** Yau TK. Complications of radiation therapy. In: Nasopharyngeal Carcinoma. VFH Chong, SY Tsao (Eds). Singapore: Armour Publishing Pte Ltd, pp 114-127, 1997.
20. **Lee AWM.*** Complications of radiotherapy. In: Nasopharyngeal Carcinoma. CA Van Hasselt, A Gibb (Eds), 1st edition. Hong Kong: Chinese University Press, pp 221-234, 1991.

Articles in Peer-reviewed Journals

1. Guan XY, Tiu YC, Gong L, Zhang Y, Luo J, Yang Y, Tang Y, **Lee AWM**. GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway. Cancer Gene Therapy. Accepted
2. Chow JCH, **Lee AWM**, Wong CHL, Ng WT, Ferlito A. Epstein-Barr virus directed screening for nasopharyngeal carcinoma in individuals with positive family history: a systematic review. Oral Oncology. Manuscript submitted.

3. Guan XY, Gong L, Luo J, Zhang Y, Yang Y, Li SS, Fang X, Huang J, Chow LKY, Chung DLS, Huang J, Huang C, Bai L, Tiu YC, Wu P, Wang Y, Tsao SW, Kwong DLW, **Lee AWM**, Dai W. Integrated multiomics analysis reveals CD70+ nasopharyngeal carcinoma cells as a vital metabolic switch for Treg development and suppressive activity. *Cancer Discovery*. Submitted.
4. ... **Lee AWM**... Inhibition of LOXL2 overcomes adhesion-dependent drug resistance in the collagen-enriched liver cancer microenvironment. *Hepatology Communications*. Accepted.
5. Chan SK, O'Sullivan B, Huang SH, Chau TC, Lam KO, Chan SY, Tong CC, Vardhanabhuti V, Kwong DLW, Ng CY, Leung TW, Luk MY, **Lee AWM**, Choi HCW, Lee VHF. Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated de novo Metastatic Nasopharyngeal Carcinoma. *Cancers*. Accepted.
6. Mui AWL, **Lee AWM**, Ng WT, Lee VHF, Vardhanabhuti V, Man SSY, Chua DTT, Guan XY. Correlations of tumour permeability parameters from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) with apparent diffusion coefficient (ADC) in nasopharyngeal carcinoma. *Magn Reson Imaging journal*. Accepted.
7. Xu Z, Yang L, Ng WT, El Helali A, Lee VHF, Ma L, Liu Q, Li J, Shen L, Huang J, Zha J, Zhou C, **Lee AWM**, Chen L. A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of Cisplatin. *Front Oncol*. 2022 Apr 27;12:842281. doi: 10.3389/fonc.2022.842281. eCollection 2022.
8. **Lee AWM**, Ng WT, Choi CW, But B, NGAN RKC, Tung S, Cheng A, Kwong DLW, Lu TX, Chan A, Yiu H, Lee S, Wong F, Yuen KT, Chappell R. Exploratory Study of NPC-0501 Trial - Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma. *Clinical Cancer Research*. 2022 Apr 5;clincanres.3375.2021. doi: 10.1158/1078-0432.CCR-21-3375. Online ahead of print.
9. López F, Shah JP, Beitler JJ, Snyderman CH, Lund V, Piazza C, Mäkitie AA, Guntinas-Lichius O, Rodrigo JP, Kowalski LP, Quer M, Shaha A, Homma A, Sanabria A, Ferrarotto R, **Lee AWM**, Lee VHF, Rinaldo A, Ferlito A. The Selective Role of Open and Endoscopic Approaches for Sinonasal Malignant Tumours. *Adv Ther*. 2022 Jun;39(6):2379-2397. doi: 10.1007/s12325-022-02080-x. Epub 2022 Mar 30.
10. Chan SK, Lin C, Huang SH, Chau TC, Guo QJ, O'Sullivan B, Lam KO, Chau SC, Chan SY, Tong CC, Vardhanabhuti V, Kwong DLW, So TH, Ng CY, Leung TW, Luk MY, **Lee AWM**, Choi HCW, Pan JJ, Lee VHF. Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma. *Oral Oncol*. 2022 Mar;126:105736. doi: 10.1016/j.oraloncology.2022.105736. Epub 2022 Feb 1.
11. Chan WL, Chow JCH, Xu ZY, Li J, Kwong WTG, Ng WT, **Lee AWM**. Management of Nasopharyngeal Carcinoma in Elderly Patients. *Frontiers in Oncology, section Head and Neck Cancer*. *Front Oncol*. 2022 Feb 1;12:810690. doi: 10.3389/fonc.2022.810690. eCollection 2022.
12. Ng WT, Chua MLK, **Lee AWM**. Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma—Magic Bullet or Pandora's Box? *JAMA Oncology*. 2022 Feb 17. doi: 10.1001/jamaoncol.2021.7365. Online ahead of print.
13. Ng WT, Chua MLK, **Lee AWM**. Identifying Patients with 'Low-risk' Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma EBV DNA for Chemotherapy De-intensification: Quo Vadis? *Journal of Clinical Oncology*. 2022 Feb 25;JCO2200099. doi: 10.1200/JCO.22.00099. Online ahead of print.

14. Chow JCH, Cheung KM, Cheung GTC, Tam AHP, Lui JCF, Lee FKH, Au KH, Ng WT, **Lee AWM**, You HHY. Dose-volume predictors of post-radiation primary hypothyroidism in head and neck cancer: A systematic review. *Clin Transl Radiat Oncol.* 2022 Jan 24;33:83-92. doi: 10.1016/j.ctro.2022.01.001. eCollection 2022 Mar.
15. Ng WT, But B, Choi HCW, de Bree R, **Lee AWM**, Lee VHF, López F, Mäkitie AA, Rodrigo JP, Saba NF, Tsang RKY, Ferlito A. Application of Artificial Intelligence for Nasopharyngeal Carcinoma Management – A Systematic Review. *Cancer Management and Research.* 2022 Jan 26; 14: 339–366. <https://doi.org/10.2147/CMAR.S341583>.
16. Chan SK, Chau SC, Chan SY, Tong CC, Lam KO, Lai-Wan Kwong D, Leung TW, Luk MY, **Lee AW**, Choi HC, Lee VH. Incidence and Demographics of Nasopharyngeal Carcinoma in Cheung Chau Island of Hong Kong-A Distinct Geographical Area With Minimal Residential Mobility and Restricted Public Healthcare Referral Network. *Cancer Control.* Jan-Dec 2021;28:10732748211047117. doi: 10.1177/10732748211047117.
17. Tang SQ, Chen L, Li WF, Chan ATC, Huang SH, Chua MLK, O'Sullivan B, **Lee AWM**, Lee NY, Zhang Y, Chen YP, Xu C, Sun Y, Tang LL, Ma J. Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial. *Radiother Oncol.* 2021 Dec 28;167:179-186. doi: 10.1016/j.radonc.2021.12.029. Online ahead of print.
18. Tan YN, Li YP, Huang JD, Luo M, Li SS, **Lee AW**, Hu FQ, Guan XY. Thermal-sensitive lipid nanoparticles potentiate anti-PD therapy through enhancing drug penetration and T lymphocytes infiltration in metastatic tumor. *Cancer Lett.* 2021 Dec 1;522:238-254. doi: 10.1016/j.canlet.2021.09.031. Epub 2021 Sep 24.
19. Lau KS, Cheung BMF, Lam KO, Chan SY, Lam KM, Yeung CF, Hung IFN, Kwong DLW, Tong CC, Leung TW, Luk MY, **Lee AWM**, Yuen KK, Lee VHF. Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report. *BMC Infect Dis.* 2021 Nov 10;21(1):1148. doi: 10.1186/s12879-021-06845-7.
20. Blanchard P, **Lee AWM**, Carmel A, Ng WT, Ma J, Chan ATC, Hong RL, Chen MY, Chen L, Li WF, Huang PY, Kwong DLW, Poh SSX, Ngan R, Mai HQ, Ollivier C, Fountzilas G, Li Z, Bourhis J, Aupérin A, Lacas B, Pignon JP, MAC-NPC collaborative Group. Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients. *Clin Transl Radiat Oncol.* 2021 Nov 26;32:59-68. doi: 10.1016/j.ctro.2021.11.007. eCollection 2022 Jan.
21. Lam TC, Tsang KC, Choi HC, Lee VH, Lam KO, Chiang CL, So TH, Chan WW, Nyaw SF, Lim F, Lau JO, Chik J, Kong FM, **Lee AW**. Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure. *Lung Cancer.* 2021 Sep;159:18-26. doi: 10.1016/j.lungcan.2021.07.004. Epub 2021 Jul 16.
22. Wang L, Mai ZM, Ngan RKC, Ng WT, Lin JH, Kwong DLW, Chiang SC, Yuen KT, Ng AWY, Ip DKM, Chan YH, **Lee AWM**, Lung ML, Ho SYD, Lam TH. Dose-Response Reduction in Risk of Nasopharyngeal Carcinoma From Smoking Cessation: A Multicenter Case-Control Study in Hong Kong, China. *Front. Oncol.*, 27 September 2021| <https://doi.org/10.3389/fonc.2021.699241>.
23. Gong L, Kwong DLW, Dai W, Wu P, Wang Y, **Lee AWM**, Guan XY. The Stromal and Immune Landscape of Nasopharyngeal Carcinoma and Its Implications for Precision Medicine Targeting the Tumor Microenvironment. *Front. Oncol.*, 10 September 2021. <https://doi.org/10.3389/fonc.2021.744889>

24. Chiang CL, Guo Q, Ng WT, Lin S, Ma TSW, Xu Z, Xiao Y, Li J, Lu T, Choi HCW, Chen W, Chau ESC, Luk PHY, Huang SS, O'Sullivan B, Pan J, **Lee AWM**. Prognostic Factors for Overall Survival in Nasopharyngeal Cancer and Implication for TNM Staging by UICC: A Systematic Review of the Literature. *Frontiers in Oncology, section Head and Neck Cancer*. 02 September 2021| <https://doi.org/10.3389/fonc.2021.703995>
25. Mai ZM, Ngna RKC, Ng WT, Lin JH, Kwong DLW, Yuen KT, Lee CK, Leung JNS, Ip DKM, Chan YH, **Lee AWM**, Lung ML, Lam TH, Ho SY. Low vitamin D exposure and risk of nasopharyngeal carcinoma: observational and genetic evidence from a multicenter case-control study. *Clinical Nutrition*. 2021 Sep;40(9):5180-5188. doi: 10.1016/j.clnu.2021.07.034. Epub 2021 Aug 8.
26. Yip PL, Lee SF, Choi HCW, Chan SPC, Cheung AKW, Chow JCH, Cheung KM, Lai JWY, Lee VHF, Lam KO, Chiang CL, Wong ECY, Poon DMC, Tong M, Au KH, Ng WT, Ngan RKC, **Lee AWM**, Tung SY. External Validation of a Nomogram to Predict Survival and Benefit of Concurrent Chemoradiation for Stage II Nasopharyngeal Carcinoma. *Cancers*. 2021 Aug 25; 13(17): 4286; <https://doi.org/10.3390/cancers13174286>
27. Corry J, Ng WT, Moore A, Choi HCW, Le Q, Holmes S, Munandar A, Wang S, Camacho A, Setakornnukul J, Jiarpinitnun C, Hiep PN, Laskar SG, Benjaafar N, Faheem M, Jin F, Ammar CNB, Ali R, Boualga K, Abdelwahab S, Sommat K, Tao Y, O'Sullivan B, Lee N, Zubizaretta E, Prajogi B, Hopkins K, Rosenblatt E, **Lee AWM**. Can Radiation Therapy Quality Assurance Improve Nasopharyngeal Cancer Outcomes in Low- and Middle-Income Countries: Reporting the First Phase of a Prospective International Atomic Energy Agency Study. *Int J Radiat Oncol Biol Phys*. 2021 Aug 18;S0360-3016(21)02682-1. doi: 10.1016/j.ijrobp.2021.08.013. Online ahead of print.
28. Nuyts S, Bollen H, Eisbruch A, Corry J, Strojjan P, Mäkitie AA, Langendijk JA, Mendenhall WM, Smeets R, DeBree R, **Lee AWM**, Rinaldo A, Ferlito A. Unilateral versus bilateral nodal irradiation: Current evidence in the treatment of squamous cell carcinoma of the head and neck. *Head Neck*. 2021 Sep;43(9):2807-2821. doi: 10.1002/hed.26713. Epub 2021 Apr 19.
29. Mui AWL, **Lee AWM**, Lee VHF, Ng WT, Vardhanabhuti V, Man SSS, Chua DTT, Law SCK, Guan XY. Prognostic and therapeutic evaluation of nasopharyngeal carcinoma by dynamic contrast-enhanced (DCE), diffusion-weighted (DW) magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). *Magn Reson Imaging*. 2021 Jul 8;S0730-725X(21)00121-1. doi: 10.1016/j.mri.2021.07.003. Online ahead of print.
30. Chua MLK, Ng WT, **Lee AWM**. Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma. *Lancet Oncol*. 2021 Jun;22(6):e217. doi: 10.1016/S1470-2045(21)00143-1.
31. **Lee AWM**, Lee VHF, Ng WT, Strojjan P, Saba NF, Rinaldo A, Willems SM, Rodrigo JP, Forastiere AA, Ferlito A. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. *European Journal of Cancer*. 2021 Jun 18; 153: 109-122. <https://doi.org/10.1016/j.ejca.2021.05.022>.
32. Gong L, Kwong D, Dai W, Wu P, Li S, Yan Q, Zhang Y, Zhang B, Fang Xi, Liu L, Luo M, Liu B, Chow L, Chen Q, Huang J, Lee V, Lam K, Lo A, Chen Z, Wang Y, **Lee AWM**, Guan XY. Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma. *Nature Communications*. 2021 Mar 9;12(1):1540. doi: 10.1038/s41467-021-21795-z.
33. Ng WT, Tsang RKY, Beitler JJ, de Bree R, Coca-Pelaz A, Eisbruch A, Guntinas-Lichius O, **Lee AWM**, Mäkitie AA, Mendenhall WM, Nuyts S, Rinaldo A, Robbins KT, Rodrigo JP,

- Silver CE, Simo R, Smee R, Strojan P, Takes RP, Ferlito A. Contemporary management of the neck in nasopharyngeal carcinoma. *Head Neck*. 2021 Jun;43(6):1949-1963. doi: 10.1002/hed.26685. Epub 2021 Mar 29.
34. Choi HCW, Chan SK, Lam KO, Chan SY, Chau SC, Kwong DLW, Leung TW, Luk MY, **Lee AWM**, Lee VHF. The Most Efficacious Induction Chemotherapy Regimen for Locoregionally Advanced Nasopharyngeal Carcinoma: A Network Meta-analysis. *Frontiers in Oncology*. 25 February 2021; <https://doi.org/10.3389/fonc.2021.626145>.
 35. Ng WT, Soong YL, Ahn YC, AlHussain H, Choi HC, Corry J, Grégoire V, Harrington KJ, Hu CS, Jensen K, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Pan JJ, Peters LJ, Poh SS, Rosenthal DI, Sanguineti G, Tao Y, Wee JT, Yom SS, Chua MLK, **Lee AWM***. International Recommendations on Re-irradiation by Intensity-modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys*. 2021 Feb 2;S0360-3016(21)00115-2. doi: 10.1016/j.ijrobp.2021.01.041.
 36. Mai ZM, Ngan RKC, Kwong DLW, Ng WT, Yuen KT, Ip DKM, Chan YH, **Lee AWM**, Ho SY, Lung ML, Lam TH. Dietary fiber intake from fresh and preserved food and risk of nasopharyngeal carcinoma: observational evidence from a Chinese population. *Nutr J*. 2021 Feb 2;20(1):14. doi: 10.1186/s12937-021-00667-8.
 37. Mao Y, Wang S, Lydiatt W, Shah JP, Colevas AD, **Lee AWM**, O'Sullivan B, Guo R, Luo W, Chen Y, Tian L, Tang L, Sun Y, Liu L, Ren J, Ma J. Unambiguous advanced radiologic extranodal extension determined by MRI predicts worse outcomes in nasopharyngeal carcinoma: Potential improvement for future editions of N category systems. *Radiother Oncol*. 2021 Jan 28;157:114-121. doi: 10.1016/j.radonc.2021.01.015. Online ahead of print.
 38. Chan SK, Chan SY, Tong CC, Lam KO, Kwong DLW, Leung TW, Luk MY, **Lee AWM**, Choi HCW, Lee VHF. Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinoma: A pooled analysis of two prospective studies. *Oral Oncol*. 2021 Jan 25;114:105158. doi: 10.1016/j.oraloncology.2020.105158. Online ahead of print.
 39. Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH, Wee JTS, Whitley AC, Yi JY, Yom SS, Chan ATC, Hu CS, Lang JY, Le QT, **Lee AWM**, Lee N, Lin JC, Ma B, Morgan TJ, Shah J, Sun Y, Ma J. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. *J Clin Oncol*. 2021 Jan 6;JCO2003237. doi: 10.1200/JCO.20.03237. Online ahead of print.
 40. McDowell L, Rischin D, **Lee AMW**. Locoregional Radiation Therapy for De Novo Metastatic Nasopharyngeal Cancer: One Size Fits All? *Int J Radiat Oncol Biol Phys*. 2021 Jan 1;109(1):131-133. doi: 10.1016/j.ijrobp.2020.10.001.
 41. Ning L, Ko JMY, Yu VZ, Ng HY, Chan CKC, Tao L, Lam SY, Leong MML, Ngan RKC, Kwong DLW, **Lee AWM**, Ng WT, Cheng A, Tung S, Lee VHF, Lam KO, Kwan CK, Li WS, Yau S, Bei JX, Lung ML. Nasopharyngeal carcinoma MHC region deep sequencing identifies HLA and novel non-HLA TRIM31 and TRIM39 loci. *Commun Biol*. 2020 Dec 11;3(1):759. doi: 10.1038/s42003-020-01487-y.
 42. Mendenhall WM, Strojan P, **Lee AWM**, Rinaldo A, Eisbruch A, Ng WT, Smee R, Ferlito A. Radiotherapy in the management of glottic squamous cell carcinoma. *Head Neck*. 2020 Dec;42(12):3558-3567. doi: 10.1002/hed.26419. Epub 2020 Sep 8.

43. Chow JCH, Tam AHP, Cheung KM, Lee VHF, Chiang CL, Tong M, Wong ECY, Cheung AKW, Chan SPC, Lai JWY, Ngan RKC, Ng WT, **Lee AWM**, Au KH. Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSG. *Oral Oncology*. 2020 Dec;111:105012. doi: 10.1016/j.oraloncology.2020.105012. Epub 2020 Sep 24.
44. Li JS, Lam TC, Jing HM, Chen X, Cao MY, Huang C, Yang L, Xu ZY, Jiang Y, Li SS, Chen F, Han Y, Zhang YS, Lam KO, **Lee AWM**. Quality of end-of-life care of advanced cancer patients in mainland China-a retrospective cohort of 441 hospital-death in a public funded comprehensive hospital. *Ann Palliat Med*. 2020 Nov;9(6):4514-4521. doi: 10.21037/apm-19-268. Epub 2020 Jul 14.
45. Xue Z, Lui VWY, Li Y, Lin J, You C, Li X, Piao W, Yuan H, Khong PL, Lo LW, Cheung LWT, Lee VHF, **Lee AWM**, Tsao SW, Tsang CM. Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma. *Journal of Experimental & Clinical Cancer Research*. 2020 Nov 26;39(1):262. doi: 10.1186/s13046-020-01763-z.
46. Mai ZM, Lin JH, Ngan RKC, Kwong DLW, Ng WT, Ng AWY, Ip KM, Chan YH, **Lee AWM**, Ho SY, Lung ML, Lam TH. Solar ultraviolet radiation and vitamin D deficiency on Epstein-Barr virus reactivation: observational and genetic evidence from a nasopharyngeal carcinoma endemic population. *Open Forum Infect Dis*. 2020 Sep 12;7(10):ofaa426. doi: 10.1093/ofid/ofaa426. eCollection 2020 Oct.
47. Chan SK, Choi CW, Lam KO, Chan SY, Chau SC, Kwong DLW, Leung TW, Luk MY, **Lee AWM**, Lee VHF. 943P The most optimal induction chemotherapy regimen for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis. *Annals of Oncology*. 2020 Sep; 31 (4): S673. doi:https://doi.org/10.1016/j.annonc.2020.08.1058.
48. Tseng M, Ho F, Leong YH, Wong LC, Tham IWK, Cheo T, **Lee AWM**. Emerging radiotherapy technologies and trends in nasopharyngeal cancer. *Cancer Commun (Lond)*. 2020 Sep;40(9):395-405. doi: 10.1002/cac2.12082.
49. Yan K, Wang X, Lam W, Vardhanabhuti V, **Lee AWM**, Pang H. Radiomics Analysis Using Stability Selection Supervised Component Analysis for Right-censored Survival Data. *Comput Biol Med*. 2020 Sep;124:103959. doi: 10.1016/j.compbimed.2020.103959. Epub 2020 Aug 6.
50. Chan SK, Chan SY, Choi CW, Tong CC, Lam KO, Kwong DLW, Vardhanabhuti V, Leung TW, Luk MY, **Lee AWM**, Lee VHF. Prognostication of Half-Life Clearance of Plasma EBV DNA in Previously Untreated Non-metastatic Nasopharyngeal Carcinoma Treated With Radical Intensity-Modulated Radiation Therapy. *Frontiers in Oncology*. 2020 Aug 21;10:1417. doi: 10.3389/fonc.2020.01417. eCollection 2020.
51. **Lee AWM**, Ngan RKC, Ng WT, Tung SY, Cheng AAC, Kwong DLW, Lu TX, Chan ATC, Sze HCK, Yiu HHY, Wong FCS, Yuen KT, Chappell R, Choi HCW. NPC-0501 Trial on the Value of Changing Chemoradiotherapy Sequence, Replacing 5-fluorouracil With Capecitabine, and Altering Fractionation for Patients with Advanced Nasopharyngeal Carcinoma. *Cancer*. 2020 Aug 15;126(16):3674-3688. doi: 10.1002/cncr.32972. Epub 2020 Jun 4.
52. Chan LS, Lung HL, Ngan RKC, **Lee AWM**, Tsao SW, Lo KW, Kahn M, Lung ML, Wieser R, Mak NK. Role of miR-96/EVI1/miR-449a Axis in the Nasopharyngeal Carcinoma Cell Migration and Tumor Sphere Formation. *Int J Mol Sci*. 2020 Jul 31;21(15):E5495. doi: 10.3390/ijms21155495.

53. Mehanna H, Gillison M, **Lee AWM**, von Zeidler SV, Porceddu S, Head and Neck International Group (HNCIG). Adapting Head and Neck Cancer Management in the Time of COVID-19. *Int J Radiat Oncol Biol Phys*. 2020 Jul 15;107(4):628-630. doi: 10.1016/j.ijrobp.2020.04.017. Epub 2020 Apr 18.
54. Kowalski LP, Sanabria A, Ridge JA, Ng WT, de Bree R, Rinaldo A, Takes RP, Mäkitie AA, Carvalho AL, Bradford CR, Paleri V, Hartl DM, Vander Poorten V, Nixon IJ, Piazza C, Lacy P, Rodrigo JP, Guntinas-Lichius O, Mendenhall WM, D'Cruz A, **Lee AWM**, Ferlito A. COVID-19 pandemic: Effects and evidence-based recommendations for otolaryngology and head and neck surgery practice. *Head Neck*. 2020 Jun;42(6):1259-1267. doi: 10.1002/hed.26164. Epub 2020 Apr 15.
55. **Lee AWM***, Xu ZY, Lin L, Xu J, Yang J, Lee E, Hui T, Cheung J. Advocacy to Provide Good Quality Oncology Services During the COVID-19 Pandemic - Actions at 3-Levels. *Radiotherapy and Oncology*. 2020 May 7;149:25-29. doi: 10.1016/j.radonc.2020.04.031.191.
56. Ng WT, Corry J, Langendijk JA, **Lee AWM**, Mäkitie A, Mendenhall WM, Rinaldo A, Rodrigo JP, Saba NF, Smee R, Strojan P, Suárez C, Vermorken JB, Ferlito A. Current management of stage IV nasopharyngeal carcinoma without distant metastasis. *Cancer Treat Rev*. 2020 Apr;85:101995. doi: 10.1016/j.ctrv.2020.101995. Epub 2020 Feb 21.
57. Ng WT, Lee MC, Fung NT, Wong EC, Cheung AK, Chow JC, Au KH, Poon DM, Lai JW, Chiang CL, Choi HC, Chau TC, Lee VH, **Lee AWM**. Dose Volume Effects of Re-irradiation for Locally Recurrent Nasopharyngeal Carcinoma. *Head Neck*. 2020 Feb;42(2):180-187. doi: 10.1002/hed.25988. Epub 2019 Oct 16.
58. Nicholls JM, Lee VHF, Chan SK, Tsang KC, Choi CW, Kwong DLW, Lam KO, Chan SY, Tong CC, So TH, Leung TW, Luk MY, Khong PL, **Lee AWM**. Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes. *Br J Cancer*. 2019 Oct; 121(8):690-698. doi: 10.1038/s41416-019-0575-6. Epub 2019 Sep 17.
59. **Lee AWM**, Ng WT, Pan JJ, Chiang CL, Poh SS, Choi HC, Ahn YC, AlHussain H, Corry J, Grau C, Grégoire V, Harrington KJ, Hu CS, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Peters LJ, Rosenthal DI, Sanguineti G, Soong YL, Tao Y, Yom SS, Wee JT. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys*. 105(3):567-580, 2019. doi: 10.1016/j.ijrobp.2019.06.2540.
60. Ng WT, Wong ECY, Cheung AKW, Chow JCH, Poon DMC, Lai JWY, Chiang CL, Choi HCW, Chau TC, Lee VHF, **Lee AWM**, Tam AHP, Au KH. Patterns of care and treatment outcomes for local recurrence of NPC after definite IMRT-A study by the HKNPCSG. *Head Neck*. 2019 Oct;41(10):3661-3669. doi: 10.1002/hed.25892. Epub 2019 Jul 27.
61. **Lee AWM**, Ng WT, Chan JYW, Corry J, Mäkitie A, Mendenhall WM, Rinaldo A, Rodrigo JP, Saba NF, Strojan P, Suárez C, Vermorken JB, Yom SS, Ferlito A. Management of Locally Recurrent Nasopharyngeal Carcinoma. *Cancer Treatment Reviews*. 2019 Aug 21;79:101890. doi: 10.1016/j.ctrv.2019.101890. [Epub ahead of print]
62. Lee VHF, Lam TC, Jing HM, Liu F, Zhang YS, Huang JJ, **Lee AWM**. Integrative Palliative Cancer Care in Hong Kong: An Overview and an Example from the East. *Clin Oncol (R Coll Radiol)*. 2019 Aug;31(8):589-594. doi: 10.1016/j.clon.2019.06.001. Epub 2019 Jun 21.
63. Lee VHF, Chan JYW, Vardhanabhuti V, Kwong DLW, Leung TW, Chan SY, Tong CC, Xu ZY, Shen L, **Lee AWM**. Advancing Care for Head and Neck Cancers in a Multidisciplinary

- Tumour Board in the East. *Clin Oncol (R Coll Radiol)*. 2019 Aug;31(8):549-559. doi: 10.1016/j.clon.2019.05.023.
64. Choi HCW, Lam KO, Pang HHM, Tsang SKC, Ngan RKC, **Lee AWM**. Global comparison of cancer outcomes: standardization and correlation with healthcare expenditures. *BMC Public Health*. 2019 Aug 7;19(1):1065. doi: 10.1186/s12889-019-7384-y.
 65. Brierley J, O'Sullivan B, Asamura H, Byrd D, Huang SH, **Lee AWM**, Piñeros M, Mason M, Moraes FY, Rösler W, Rous B, Torode J, van Krieken JH, Gospodarowicz M. Global Consultation on Cancer Staging: promoting consistent understanding and use. *Nat Rev Clin Oncol*. 2019 Aug 6. doi: 10.1038/s41571-019-0253-x. [Epub ahead of print]
 66. Du R, Lee VHF, Yuan H, Lam KO, Pang HH, Chen Y, Lam EY, Khong PL, **Lee AWM**, Kwong DLW, Vardhanabhuti V. Radiomics Model to Predict Early Progression of Nonmetastatic Nasopharyngeal Carcinoma after Intensity Modulation Radiation Therapy: A Multicenter Study. *Radiology: Artificial Intelligence*. 2019 Jul 10; 1(4): p.e180075. <https://doi.org/10.1148/ryai.2019180075>.
 67. Xiu D, Fung YL, Lau BH, Wong DFK, Chan CHY, Ho RTH, So TH, Lam TC, Lee VH, **Lee AWM**, Chow SF, Lim FM, Tsang MW, Chan CLW, Chow AYM. Comparing dyadic cognitive behavioral therapy (CBT) with dyadic integrative body-mind-spirit intervention (I-BMS) for Chinese family caregivers of lung cancer patients: a randomized controlled trial. *Support Care Cancer*. 2019 Jul 6. doi: 10.1007/s00520-019-04974-z. [Epub ahead of print]
 68. Chen L, Chan LS, Lung HL, Yip TTC, Ngan RKC, Wong JWC, Lo KW, Ng WT, **Lee AWM**, Tsao GSW, Lung ML, Mak NK. Crucifera sulforaphane (SFN) inhibits the growth of nasopharyngeal carcinoma through DNA methyltransferase 1 (DNMT1)/Wnt inhibitory factor 1 (WIF1) axis. *Phytomedicine*. 2019 Jul 29; 63: 153058. doi:10.1016/j.phymed.2019.153058.
 69. Thu Le Q, Dimitrios Colevas A, O'Sullivan B, **Lee AWM**, Lee N, Ma B, Siu LL, Waldron J, Lim CM, Riaz N, Lynn J, Malik S. Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. *J Natl Cancer Inst*. 2019 Jul 1;111(7):655-663. doi: 10.1093/jnci/djz044.
 70. Mai ZM, Lin JH, Ngan RKC, Kwong DLW, Ng WT, Ng AWY, Yuen KT, Ip DKM, Chan YH, **Lee AWM**, Ho SY, Lung ML, Lam TH. Milk consumption across life periods in relation to lower risk of nasopharyngeal carcinoma: A multicentre case-control study. *Frontiers in Oncology*. 2019 Apr 10;9:253. doi: 10.3389/fonc.2019.00253. eCollection 2019.
 71. Ruysscher DD, Niedermann G, Burnet N, Siva S, **Lee AWM**, Hegi F. Radiotherapy toxicity. *Nature Reviews Disease Primers*. 2019 Feb 21;5(1):13. doi: 10.1038/s41572-019-0064-5.
 72. Mendenhall WM, Strojan P, Beitler JJ, Langendijk JA, Suarez C, **Lee AWM**, Rinaldo A, Rodrigo JP, Smee R, Eisbruch A, Harrison LB, Corry J, Ferlito A. Radiotherapy for parapharyngeal space tumors. *Am J Otolaryngol*. 2019 Mar - Apr;40(2):289-291. doi: 10.1016/j.amjoto.2018.12.010. Epub 2018 Dec 21.
 73. Chan LS, Man OY, Kwok HH, Chen L, Chan KC, Lung HL, Ngan RK, Wong RN, Lo KW, **Lee AWM**, Tsao GS, Kahn M, Lung ML, Mak NK. The Wnt modulator ICG-001 mediates the inhibition of nasopharyngeal carcinoma cell migration in vitro via the miR-150/CD44 axis. *Int J Oncol*. 2019 Mar;54(3):1010-1020. doi: 10.3892/ijo.2018.4664. Epub 2018 Dec 12.
 74. Lee VH, Kwong DL, Leung TW, Choi CW, O'Sullivan B, Lam KO, Lai V, Khong PL, Chan SK, Ng CY, Tong CC, Ho PP, Chan WL, Wong LS, Leung DK, Chan SY, So TH, Luk MY, **Lee AWM**. The addition of pretreatment plasma Epstein-Barr virus DNA into the 8th

- edition of nasopharyngeal cancer TNM stage classification. *Int J Cancer*. 144(7):1713-1722, 2019. doi: 10.1002/ijc.31856.
75. Mendenhall WM, Suárez C, Genden EM, de Bree R, Strojan P, Langendijk JA, Mäkitie AA, Smee R, Eisbruch A, **Lee AWM**, Rinaldo A, Ferlito A. Parameters Associated With Mandibular Osteoradionecrosis. *Am J Clin Oncol*. 2018 Dec;41(12):1276-1280. doi: 10.1097/COC.0000000000000424. PubMed PMID: 29360644.
 76. Lee VH, Lam KO, Chang AT, Lam TC, Chiang CL, So TH, Choi CW, **Lee AWM**. Management of Nasopharyngeal Carcinoma: Is Adjuvant Therapy Needed? *J Oncol Pract*. 2018 Oct;14(10):594-602. doi: 10.1200/JOP.18.00219.
 77. Le QT, Yom SS, Wee JTS, **Lee AWM**, Grau C, Grégoire V, Porceddu S, Welch JJ, Mehanna H. In Regard to Beadle and Anderson. *Int J Radiat Oncol Biol Phys*. 2018 Sep 1;102(1):229-230. doi: 10.1016/j.ijrobp.2018.05.015. Epub 2018 Aug 8.
 78. Lee VH, Kwong DL, Leung TW, Choi HCW, O'Sullivan B, Lai V, Lam KO, Tong CC, Ng CY, Chan SY, Ho PP, Chan WL, Leung DK, Chan SK, Tsang KC, Khong PL, Luk MY, **Lee AWM**. 5-Year Results of the Prognostic Roles of Serial Post-Intensity-Modulated Radiation Therapy Undetectable Plasma EBV DNA for Non-Metastatic Nasopharyngeal Carcinoma. *International Journal of Radiation Oncology Biology Physics*. 102(3): S126-127, 2018. doi: 10.1016/j.ijrobp.2018.06.315.
 79. Liu X, Zhang Y, Tang LL, Le QT, Chua MLK, Wee JTS, Lee NY, O'Sullivan B, **Lee AWM**, Sun Y, Ma J. Characteristics of Radiotherapy Trials Compared with other Oncological Clinical Trials in the Past 10 Years. *Jama Oncology*. 2018 Aug 1;4(8):1073-1079. doi: 10.1001/jamaoncol.2018.0887.
 80. Au KH, Ngan RKC, Ng AWY, Poon DMC, Ng WT, Yuen KT, Lee VHF, Tung SY, Chan ATC, Henry CK Sze HCK, Cheng ACK, **Lee AWM**, Kwong DLW, Anthony HP Tam AHP. Treatment Outcomes of Nasopharyngeal carcinoma in modern era after Intensity Modulated Radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study) *Oral Oncol*. 2018;77:16-21, doi: 10.1016/j.oraloncology.2017.12.004.
 81. Ko JMY, Tsang KHK, Dai W, Choi SSA, Leong MML, Ngan RKC, Kwong DLWS, Cheng A, **Lee AWM**, Ng WT, Tung S, Lee VHF, Lam KO, Chan CKC, Lung ML. Leukocyte telomere length associates with Nasopharyngeal risk and survival in Hong Kong Chinese. *Int J Cancer*. 2018 Nov 1;143(9):2289-2298. doi: 10.1002/ijc.31617. Epub 2018 Aug 7.
 82. Mai ZM, Lin JH, Chiang SC, Ngan RK, Kwong DL, Ng WT, Ng AW, Yuen KT, Ip KM, Chan YH, **Lee AWM**, Ho SY, Lung ML, Lam TH. Test-retest reliability of a computer-assisted self-administered questionnaire on early life exposure in a nasopharyngeal carcinoma case-control study. *Scientific reports*. 2018 May 4; 8:7052, doi: 10.1038/s41598-018-25046y.
 83. Ng WT, Tung SY, Lee V, Ngan RKC, Choi HCW, Chan LLK, Leung TW, Siu LL, Lu TX, Tan T, Tan EH, Sze HCK, Ng AWY, Yiu HHY, O'Sullivan B, Chappell R, **Lee AWM***. Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma-Exploration for Achieving Optimal 10-Year Therapeutic Ratio. *Int J Radiat Oncol Biol Phys*. 101(5):1078-1086, 2018. doi: 10.1016/j.ijrobp.2018.04.069. Epub 2018 May 2.
 84. Lau BH, Chow AYM, Wong DFK, Chan JSM, Chan CHY, Ho RTH, So TH, Lam TC, Lee VHF, **Lee AWM**, Chow SF, Chan CLW. Study protocol of a randomized controlled trial comparing integrative body-mind-spirit intervention and cognitive behavioral therapy in fostering quality of life of patients with lung cancer and their family caregivers. *J Evid Inf*

- Soc Work. 2018 May-Jun;15(3):258-276. doi: 10.1080/23761407.2018.1435325. Epub 2018 Feb 5.
85. Lam PL, Lam TC, Choi CW, **Lee AWM**, Yuen KK, Leung TW. The impact of palliative care training for oncologists and integrative palliative service in a public-funded hospital cluster-a retrospective cohort study. *Support Care Cancer*. 2018 May;26(5):1393-1399. doi: 10.1007/s00520-017-3963-6.
 86. Lee VHF, Chan SY, Tong CC, Lam KO, Kwong DLW, **Lee AWM**, Leung TW. New hope for advanced nasopharyngeal cancer – an Epstein-Barr virus-driven endemic malignancy? *Trans Cancer Res*. February 2018, 7(Supp 1): S53-S57, doi: 10.21037/tcr.2017.12.25.
 87. Fernández-Alvarez V, López F, Suárez C, Stojan P, Eisbruch A, Silver CE, Mendenhall WM, Langendijk JA, Rinaldo A, **Lee AWM**, Beitler JJ, Smeeth I, Ferlito A. Radiation-induced carotid artery lesions. *Strahlenther Onkol*. 2018 Aug;194(8):699-710. doi: 10.1007/s00066-018-1304-4. Epub 2018 Apr 20.
 88. Kessel KA, **Lee AWM**, Bentzen SM, Vikram B, Nüsslin F, Combs SE. Editorial: Data Based Radiation Oncology-Design of Clinical Trials. *Front Oncol*. 2018 Feb 16;8:34. doi: 10.3389/fonc.2018.00034. eCollection 2018.
 89. Ng WT, Ngan RKC, Kwong DLW, Tung SY, Yuen KT, Kam MKM, Sze HCK, Yiu HHY, Chan LLK, Lung ML, **Lee AWM**. Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys*. 100(3):630-638, 2018. doi: 10.1016/j.ijrobp.2017.11.038.
 90. Ng WT, Wong ECY, Lee VHF, Chan JYW, **Lee AWM***. Head and neck cancer in Hong Kong. *Japanese Journal of Clinical Oncology*. 2018 Jan 1;48(1):13-21. doi: 10.1093/jjco/hyx151.
 91. **Lee AWM**, Ng WT, Pan JJ, Poh SS, Ahn YC, AlHussain H, Corry J, Grau C, Grégoire V, Harrington KJ, Hu CS, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Peters LJ, Rosenthal DI, Soong YL, Tao Y, Yom SS, Wee JT. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. *Radiother Oncol*. 126(1):25-36, 2018. doi: 10.1016/j.radonc.2017.10.032.
 92. Yang L, Lam KO, Lee VHF, **Lee AWM**. Gefitinib-induced toxic epidermal necrolysis in a patient with metastatic non-small cell lung cancer. *Hong Kong J Radiol*. 2018; 21:e8-11, doi: 10.12809/hkjr1816416.
 93. Grégoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, Eisbruch A, Feng M, Giralt J, Gupta T, Hamoir M, Helito JK, Hu C, Hunter K, Johansen J, Kaanders J, Laskar SG, **Lee AWM**, Maingon P, Mäkitie A, Micciche' F, Nicolai P, O'Sullivan B, Poitevin A, Porceddu S, Skłodowski K, Tribius S, Waldron J, Wee J, Yao M, Yom SS, Zimmermann F, Grau C. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. *Radiother Oncol*. 2018 Jan;126(1):3-24. doi: 10.1016/j.radonc.2017.10.016. Epub 2017 Nov 24.
 94. Yue PYK, Ha WY, Lau CC, Cheung FFM, **Lee AWM**, Ng WT, Ngan RKC, Yau CC, Kwong DLW, Lung HL, Mak NK, Lung ML, Wong RNS. MicroRNA profiling study reveals miR-

- 150 in association with metastasis in nasopharyngeal carcinoma. *Sci Rep.* 2017 Sep 20;7(1):12012. doi: 10.1038/s41598-017-10695-2.
95. Stojan P, Hutcheson KA, Eisbruch A, Beitler JJ, Langendijk JA, **Lee AWM**, Corry J, Mendenhall WM, Smee R, Rinaldo A, Ferlito A. Treatment of late sequelae after radiotherapy for head and neck cancer. *Cancer Treat Rev.* 2017 Sep;59:79-92. doi: 10.1016/j.ctrv.2017.07.003. Epub 2017 Jul 18.
 96. CL Chiang, TH So, ZJ Chen, VH Lee, **Lee AWM**. Pursuit of Excellence in the Management of Nasopharyngeal Carcinoma (NPC). *International Journal of Head and Neck Science.* 1(4): 199-211, 2017, doi: 10.6696/IJHNS.2017.0104.01.
 97. **Lee AWM***, Tung SY, Ng WT, Lee V, Ngan RKC, Choi HCW, Chan LLK, Siu LL, Ng AWY, Leung TW, Yiu HHY, O'Sullivan B, Chappell R. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. *Cancer.* 123(21):4147-4157, 2017. doi: 10.1002/cncr.30850.
 98. **Lee AWM**, Tung SY, Ng WT, Ngan KC, Lee VHF, Choi CW, Chan L, Lu TX, Siu LL, Tan TWK., Ng AWY., Yiu HHY., Leung TW, O'Sullivan B, Tan EH, Chappell RJ. 10-Year Outcome on the Efficacy and Late Toxicities Attributed to the Addition of Concurrent-Adjuvant Chemotherapy for Stage III-IVB Nasopharyngeal Carcinoma (Combined Analyses of the NPC-9901 and NPC-9902 Trials), *International Journal of Radiation Oncology, Biology, Physics.* 2017; 99(2): S46-S46. doi: 10.1016/j.ijrobp.2017.06.118.
 99. Li ji-shi, Xu Zhi-yuan, Chen Zhi-jian, Chen Zhi-jian, Xu Xiao-ping, Jing Hai-man, Zhou Lue, Chen Xian, Lam Ka-on and **Lee AWM**. A New Model of Clinical Pathway for Comprehensive Management of Nasopharyngeal Carcinoma: Research and Clinical Practice. *China Cancer.* 2017; 26(2), p106-110.
 100. Lee V, Kwong D, Leung TW, Lam KO, Tong CC, **Lee AWM**. Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma – How far have we achieved? *Crit Rev Oncol Hematol.* 2017 Jun;114:13-23. doi: 10.1016/j.critrevonc.2017.03.030. Epub 2017 Apr 2.
 101. Chen YP, Chen L, Li WF, **Lee AWM**, Vermorken JB, Wee J, O'Sullivan B, Eisbruch A, Lin JC, Mai HQ, Zhang L, Guo Y, Lin AH, Sun Y, Ma J. Reporting Quality of Randomized, Controlled Trials Evaluating Combined Chemoradiotherapy in Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys.* 2017 May 1;98(1):170-176. doi: 10.1016/j.ijrobp.2017.01.214. Epub 2017 Jan 29.
 102. Lee VH, Kwong DL, Lam KO, Lai YC, Li Y, Tong CC, Ho PP, Chan WL, Wong LS, Leung DK, Chan SY, Chan FT, Leung TW, **Lee AWM**. Metronomic Oral Cyclophosphamide as Third-line Systemic Treatment or Beyond in Patients With Inoperable Locoregionally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma. *Medicine (Baltimore).* 2017 Apr;96(15):e6518. doi: 10.1097/MD.00000000000006518.
 103. Rotolo F, Pignon JP, Bourhis J, Marguet S, Leclercq J, Tong Ng W, Ma J, Chan AT, Huang PY, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Soong YL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, **Lee AWM**, Blanchard P*, Michiels S*; MAC-NPC Collaborative Group., on behalf of the MAC-NPC Collaborative Group. Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. *J Natl Cancer Inst.* 2017 Apr;109(4):djw239. doi: 10.1093/jnci/djw239.

104. Chan OS, Sze HC, Lee MC, Chan LL, Chang AT, Lee SW, Hung WM, **Lee AWM**, Ng WT. Reirradiation with intensity-modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma. *Head & Neck*. 2017 Mar;39(3):533-540. doi: 10.1002/hed.24645. Epub 2016 Nov 29.
105. Ribassin-Majed L, Marguet S, **Lee AWM**, Ng WT, Ma J, Chan AT, Huang PY, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Bourhis J, Pignon JP, Blanchard P. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. *J Clin Oncol*. 2017 Feb 10;35(5):498-505. doi: 10.1200/JCO.2016.67.4119. Epub 2016 Dec 5.
106. Choi HC, Xu W, **Lee AWM**. Reply to Nomograms need to be presented in full. *Cancer*. 2017 Jan 1;123(1):178-179. doi: 10.1002/cncr.30345. Epub 2016 Sep 14.
107. Chai AW, Cheung AK, Dai W, Ko JM, Ip JC, Chan KW, Kwong DL, Ng WT, **Lee AWM**, Ngan RK, Yau CC, Tung SY, Lee VH, Lam AK, Pillai S, Law S, Lung ML. Metastasis-suppressing NID2, an Epigenetically-silenced Gene, in the Pathogenesis of Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma. *Oncotarget*. 2016 Nov 29;7(48):78859-78871. doi: 10.18632/oncotarget.12889.
108. Zheng H, Dai W, Cheung AKL, Ko JMY, Kan R, Wong BWY, Leong MML, Deng M, Kwok TCT, J Chan, Kwong DLW, **Lee AWM**, Ng WT, Ngan RKC, Yau CC, Tung S, Lee VHF, Lam KO, Kwan CK, Li WS, Yau S, Chan KW, Lung ML. Whole-exome sequencing identifies multiple loss-of-function mutations of NF- κ B pathway regulators in nasopharyngeal carcinoma. *Proc Natl Acad Sci*. 2016 Oct 4;113(40):11283-11288. doi: 10.1073/pnas.1607606113. Epub 2016 Sep 19.
109. Lee V, Chan SY, Choi CW, Kwong D, Lam KO, Tong CC, Sze CK, Ng S, Leung TW, **Lee AWM**. Dosimetric Predictors of Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Non-metastatic Nasopharyngeal Carcinoma. *Clinical Oncology (Royal College of Radiologists)*. 2016 Aug;28(8):e52-60. doi: 10.1016/j.clon.2016.05.004. Epub 2016 May 24.
110. Pan JJ, Ng WT, Zong JF, Lee SW, Choi HC, Chan LL, Lin SJ, Guo QJ, Sze HC, Chen YB, Xiao YP, Kan WK, O'Sullivan B, Xu W, Le QT, Glastonbury CM, Colevas AD, Weber RS, Lydiatt W, Shah JP, **Lee AWM***. Prognostic Nomogram for Refining the Prognostication of the Proposed 8th Edition of the AJCC/UICC Staging System for Nasopharyngeal Cancer in the Era of Intensity-modulated Radiotherapy. *Cancer*. 15;122(21):3307-3315, 2016. doi: 10.1002/cncr.30198.
111. Strojan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M Jr, Bossi P, Worden FP, Langendijk JA, Eisbruch A, Mendenhall WM, **Lee AWM**, Harrison LB, Bradford CR, Smeets R, Silver CE, Rinaldo A, Ferlito A. Cumulative Cisplatin Dose in Concurrent Chemoradiotherapy for Head and Neck Cancer: A Systematic Review. *Head & Neck*. 2016 Apr; 38 Suppl 1:E2151-8. doi: 10.1002/hed.24026.
112. Lam KO, **Lee AWM***, Ng WT, Hopkins KI. The International Atomic Energy Agency global initiatives on nasopharyngeal cancer treatment. *Chin Clin Oncol*. 2016 Apr;5(2):27. doi: 10.21037/cco.2016.03.02.
113. Dai W, Zheng H, Cheung AK, Tang CS, Ko JM, Wong BW, Leong MM, Sham PC, Cheung F, Kwong DL, Ngan RK, Ng WT, Yau CC, Pan J, Peng X, Tung S, Zhang Z, Ji M, Chiang AK, **Lee AWM**, Lee VH, Lam KO, Au KH, Cheng HC, Yiu HH, Lung ML. Whole-exome Sequencing Identifies MST1R as a Genetic Susceptibility Gene in Nasopharyngeal

- Carcinoma. *Proc Natl Acad Sci U S A*. 2016 Mar 22;113(12):3317-22. doi: 10.1073/pnas.1523436113.
114. Lam KO, **Lee AWM***, Choi CW, Sze HCK, Zietman AL, Hopkins KI, Rosenblatt E. Global Pattern of Nasopharyngeal Cancer: Correlation of Outcome With Access to Radiation Therapy. *Int J Radiat Oncol Biol Phys*. 94 (5):1106-1112, 2016. doi: 10.1016/j.ijrobp.2015.11.047.
 115. Pan JJ, Ng WT, Zong JF, Chan LLK, O'Sullivan B, Lin SJ, Sze HCK, Chen YB, Choi HCW, Guo QJ, Kan WK, Xiao YP, W Xu, Le QT, Glastonbury CM, Colevas AD, Weber RS, Shah JP, **Lee AWM***. Proposal for the 8th Edition of AJCC/UICC Staging System for Nasopharyngeal Cancer in the Era of Intensity-Modulated Radiotherapy. *Cancer*. 122(4): 546-558, 2016. doi: 10.1002/cncr.29795.
 116. Blanchard P, **Lee AWM**, Marguet S, Leclercq J, Ng WT, Ma J, Chan ATC, Huang PY, Benhamou E, Zhu GP, Chua DTT, Chen Y, Mai HQ, Kwong DLW, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lu TX, Bourhis J, Pignon JP, on behalf of the MAC-NPC Collaborative Group*. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. *Lancet Oncol*. 16: 645–55, 2015.
 117. Kan R, Shuen WH, Lung HL, Cheung AKL, Dai W, Kwong DLW, Ng WT, **Lee AWM**, Yau CC, Ngan RKC, Tung SY, Lung ML. NF- κ B p65 Subunit Is Modulated by Latent Transforming Growth Factor- β Binding. *PLOS ONE*. doi:10.1371/journal.pone.0127239, 2015.
 118. Dai W, Cheung AKL, Ko JMY, Cheng Y, Zheng H, Ngan RKC, Ng WT, **Lee AWM**, Yau CC, Lee VHF, Lung ML. Comparative methylome analysis in solid tumors reveals aberrant methylation at chromosome 6p in nasopharyngeal carcinoma. *Cancer Medicine*. doi: 10.1002/cam4.451, 2015.
 119. Chan KC, Chan LS, Ip JCY, Lo C, Yip TTC, Ngan RKC, Wong RNS, Lo KW, Ng WT, **Lee AWM**, Tsao GSW, Kahn M, Lung ML, Mak NK. Therapeutic targeting of CBP/b-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin. *Scientific Reports*. 5: 9979. doi: 10.1038/srep09979, 2015.
 120. Sze HCK, Blanchard P, Ng WT, Pignon JP, **Lee AWM***. Chemotherapy for Nasopharyngeal Carcinoma – Current Recommendation and Controversies. *Hematology Oncology Clinics of North America*. 2015 Dec;29(6):1107-22. doi: 10.1016/j.hoc.2015.07.004. Epub 2015 Oct 20.
 121. Brouwer CL, Steenbakkers RJHM, Bourhis J, Budach W, Grau C, Grégoire V, van Herk M, **Lee AWM**, Maingon P, Nutting C, O'Sullivan B, Porceddu SV, Rosenthal DI, Sijtsema NM, Langendijk JA. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NR G Oncology and TROG consensus guidelines. *Radiotherapy and Oncology*. 2015 Oct;117(1):83-90. doi: 10.1016/j.radonc.2015.07.041.
 122. **Lee AWM**, Ma B, Ng WT, Chan ATC. Management of nasopharyngeal carcinoma – current practice and future perspective. *J Clin Oncol*. 2015 Oct 10;33(29):3356-64. doi: 10.1200/JCO.2015.60.9347. Epub 2015 Sep 8.
 123. Ng WT, Chang AT, Lee SW, Sze HC, **Lee AWM***. Chemotherapy for Nasopharyngeal Cancer: Neoadjuvant, Concomitant, and/or Adjuvant. *Curr Treat Options Oncol*. 2015 Sep;16(9):44. doi: 10.1007/s11864-015-0361-5.

124. **Lee AWM***, Ngan R, Tung S, Cheng A, Kwong D, Lu TX, Chan A, Chan L, Yiu H, Ng WT, Wong F, Yuen KT, Yau S, Cheung FY, Chan O, Choi H, Chappell R. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. *Cancer*. 2015 Apr 15;121(8):1328-38. doi: 10.1002/cncr.29208. Epub 2014 Dec 19.
125. Lung HL, Man OY, Yeung MC, Ko JM, Cheung AK, Law EW, Yu Z, Shuen WH, Tung E, Chan SH, Bangarusamy DK, Cheng Y, Yang X, Kan R, Phoon Y, Chan KC, Chua D, Kwong DL, **Lee AWM**, Ji MF, Lung ML. SAA1 polymorphisms are associated with variation in antiangiogenic and tumor-suppressive activities in nasopharyngeal carcinoma. *Oncogene*. 2015 Feb 12;34(7):878-89. doi: 10.1038/onc.2014.12. Epub 2014 Mar 10.
126. Yang X, Dai W, Kwong DL, Szeto CYY, Wong EH, Ng WT, **Lee AWM**, Ngan RKC, Yau CC, Tung SY, Lung ML. Epigenetic markers for non-invasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting. *Int J Cancer*. 2015 Feb 15;136(4):E127-35. doi: 10.1002/ijc.29192. Epub 2014 Sep 19.
127. Stojan P, Corry J, Eisbruch A, Vermorken JB, Mendenhall WM, **Lee AWM**, Haigentz M Jr, Beitler JJ, de Bree R, Takes RP, Paleri V, Kelly CG, Genden EM, Bradford CR, Harrison LB, Rinaldo A, Ferlito A. Recurrent and Second Primary Squamous Cell Carcinoma of the Head And Neck: When and How to Re-Irradiate. *Head & Neck*. 2015 Jan;37(1):134-50. doi: 10.1002/hed.23542. Epub 2014 Jan 31.
128. Sze H, Chan LLK., Ng WT, Hung AWM, Lee MCH, Chang ATY, Chan OSH, Cheung FY, Yeung RMW, **Lee AWM**. Should all nasopharyngeal carcinoma with masticator space involvement be staged as T4? *Oral Oncol*. 2014 Dec;50(12):1188-95. doi: 10.1016/j.oraloncology.2014.09.001. Epub 2014 Sep 30.
129. Kam MKM, Wong FCS, Kwong DLW, Sze HCK, **Lee AWM**. Current Controversies in Radiotherapy for Nasopharyngeal Carcinoma (NPC). *Oral Oncol*. 2014 Oct;50(10):907-12. doi: 10.1016/j.oraloncology.2013.09.013. Epub 2013 Oct 11.
130. **Lee AWM***, Sze H, Lam KO, Chen X. A Tale of Two Cities in China: Hong Kong and Shenzhen. *Int J Radiat Oncol Biol Phys*. 2014 Jul 15;89(4):704-8. doi: 10.1016/j.ijrobp.2013.12.053.
131. Ng WT, Yuen KT, Au KH, Chan OSH, **Lee AWM**. Staging of Nasopharyngeal Carcinoma – The Past, The Present and The Future. *Oral Oncol*. 2014 Jun;50(6):549-54. doi: 10.1016/j.oraloncology.2013.06.003.
132. Ng WT, Lee MCH, Chang ATY, Chan OSH, Chan LLK, Cheung FY, Hung WM, Chan CC, **Lee AWM**. The Impact of Dosimetric Inadequacy on Treatment Outcome of Nasopharyngeal Carcinoma with IMRT. *Oral Oncol*. 2014 May;50(5):506-12. doi: 10.1016/j.oraloncology.2014.01.017. Epub 2014 Feb 13.
133. Sun Y, Yu XL, **Lee AWM**, Wee JTS, Lee N Zhou GQ, Tang LL, Tao CJ, Guo R, Mao YP, Zhang R, Guo Y, Ma J. Recommendation for a Contouring Method and Atlas of Organs at Risk in Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy. *Radiother Oncol*. 2014 Mar;110(3):390-7. doi: 10.1016/j.radonc.2013.10.035. Epub 2014 Apr 7.
134. **Lee AWM***, Ng WT, Chan LLK, Hung WM, Chan CCC, Sze HCK, Chan OSH, Chang ATY, Yeung RM. Evolution of Treatment for Nasopharyngeal Cancer – Success and Setback

- in the Intensity-Modulated Radiotherapy Era. *Radiother Oncol.* 2014 Mar;110(3):377-84. doi: 10.1016/j.radonc.2014.02.003.
135. Grégoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, **Lee AWM**, Le QT, Maingon P, Nutting CK, O'Sullivan B, Porceddum SV, Lengele B. Delineation of the Neck Node Levels for Head and Neck Tumors: A 2013 Update. DAHANCA, EORTC, HKNPCSF, NCIC, CTG, NCRI, RTOG, TROG Consensus Guidelines. *Radiother Oncol.* 2014 Jan;110(1):172-81. doi: 10.1016/j.radonc.2013.10.010. Epub 2013 Oct 31.
 136. Chan KC, Ting CM, Chan PS, Lo MC, Lo KW, Curry JE, Smyth T, **Lee AWM**, Ng WT, Tsao GSW, Wong RNS, Lung ML, Mak NK. A Novel HSP90 Inhibitor AT13387 Induces Senescence in EBV-Positive Nasopharyngeal Carcinoma Cells and Suppresses Tumor Formation. *Molecular Cancer.* 2013 Oct 24;12(1):128. doi: 10.1186/1476-4598-12-128.
 137. Lau HY, Leung CM, Chan YH, **Lee AWM**, Kwong DLW, Lung ML, Lam TH. Secular Trends of Salted Fish Consumption and Nasopharyngeal Carcinoma: A Multi-Jurisdiction Ecological Study in 8 Regions from 3 Continents. *BMC Cancer.* 2013 Jun 19;13:298. doi: 10.1186/1471-2407-13-298.
 138. Chan OSH, Yeung RMW, **Lee AWM**. Maintenance Therapy in Advanced Non-Small Cell Lung Cancer: A Prime-Time for Change? *Chin Med J.* 2013 Jun;126(12):2390-8.
 139. **Lee AWM***, Sze H, Ng WT. Is Selective Neck Irradiation Safe for Node-Negative Nasopharyngeal Carcinoma? *Int J Radiat Oncol Biol Phys.* 2013 Mar 15;85(4):902-3. doi: 10.1016/j.ijrobp.2012.09.010.
 140. Luk YS, Shum JSF, Sze HCK, Chan LLK, Ng WT, **Lee AWM**. Predictive Factors and Radiological Features of Radiation-Induced Cranial Nerve Palsy in Patients with Nasopharyngeal Carcinoma following Radical Radiotherapy. *Oral Oncol.* 2013 Jan;49(1):49-54. doi: 10.1016/j.oraloncology.2012.07.011. Epub 2012 Aug 11.
 141. Cheung F, Chan O, Ng WT, Chan L. **Lee AWM**, Pang SW. The Prognostic Value of Histological Typing in Nasopharyngeal Carcinoma. *Oral Oncol.* 2012 May;48(5):429-33. doi: 10.1016/j.oraloncology.2011.11.017. Epub 2011 Dec 16.
 142. Yau TK, Shum T, **Lee AWM**, Yeung MW, Ng WT, Chan L. A Phase II Study of Pemetrexed Combined with Cisplatin in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma. *Oral Oncol.* 2012 May;48(5):441-4. doi: 10.1016/j.oraloncology.2011.12.001.
 143. **Lee AWM***, Ng WT, Chan OSH, Sze H. If Concurrent-Adjuvant Chemoradiotherapy is Beneficial for Locoregionally Advanced Nasopharyngeal Carcinoma, would Changing the Sequence to Induction-Concurrent Achieve Better Outcome? *Radiat Oncol.* 3 May 2012; 1(2):107-115, 2012. doi: 10.1007/s13566-012-0032-0.
 144. **Lee AWM***, Ng WT, Chan LK, Chan OSH, Hung WM, Chan CC, Cheng PTC, Sze H, Lam TS, Yau TK. The Strength/Weakness of the AJCC/UICC Staging System (7th Edition) for Nasopharyngeal Cancer and Suggestions for Future Improvement. *Oral Oncol.* 2012 Oct; 48(10):1007-1013. doi: 10.1016/j.oraloncology.2012.03.022. Epub 2012 Apr 22.
 145. Sze HCK, Ng WT, Chan OSH, Shum TCY, Chan LLK, **Lee AWM**. Radical Radiotherapy For Nasopharyngeal Carcinoma In Elderly Patients: The Importance Of Co-Morbidity Assessment. *Oral Oncol.* 2012 Feb;48(2):162-7. doi: 10.1016/j.oraloncology.2011.08.019. Epub 2011 Sep 16.
 146. Law ALY, Ng WT, Lee MCH, Chan ATS, Fung KH, Li F, Lao WC, **Lee AWM**. Treatment of Primary Liver Cancer Using Highly-Conformal Radiotherapy with KV-Image Guidance and Respiratory Control. *Radiother Oncol.* 2012 Jan;102(1):56-61. doi: 10.1016/j.radonc.2011.05.022. Epub 2011 Jun 2.

147. Sze HCK, Lee MCH, Hung WM, Yau TK, **Lee AWM**. Rapidarc Radiotherapy Planning for Prostate Cancer: Single-Arc and Double-Arc Techniques vs. Intensity-Modulated Radiotherapy. *Med Dosimetry*. Spring 2012;37(1):87-91. doi: 10.1016/j.meddos.2011.01.005. Epub 2011 Sep 16.
148. Chen H, Ko JMY, Wong VCL, Hyytiainen M, Keski-Oja J, Chua D, Nicholls JM, Cheung FMF, **Lee AWM**, Kwong DLW, Chiu PM, Zabarovsky ER, Tsao SW, Tao Q, Kan R, Chan SHK, Stanbridge EJ, Lung ML. LTBP-2 Confers Pleiotropic Suppression and Promotes Dormancy in a Growth Factor Permissive Microenvironment in Nasopharyngeal Carcinoma. *Cancer Lett*. 2012 Dec 1;325(1):89-98. doi: 10.1016/j.canlet.2012.06.005. Epub 2012 Jun 26.
149. Huang Z, Cheng Y, Chiu PM, Cheung FMF, Nicholls JM, Kwong DLW, **Lee AWM**, Zabarovsky ER, Stanbridge EJ, Lung HL, Lung ML. Tumor Suppressor Alpha B-Crystallin (CRYAB) Associates with the Cadherin/Catenin Adherens Junction and Impairs NPC Progression-Associated Properties. *Oncogene*. 2012 Aug 9;31(32):3709-20. doi: 10.1038/onc.2011.529. Epub 2011 Dec 12.
150. Ting CM, Wong CKC, Wong RNS, Lo KW, **Lee AWM**, Tsao GSW, Lung ML, Mak NK. Role of STAT3/5 and BCL-2/XI in 2-Methoxyestradiol-Induced Endoreduplication of Nasopharyngeal Carcinoma Cells. *Molecular Carcinogenesis*. 2012 Dec;51(12):963-72. doi: 10.1002/mc.20867. Epub 2011 Oct 17.
151. **Lee AWM***, Ng WT, Chan YH, Sze H, Chan C, Lam TH. The Battle Against Nasopharyngeal Cancer. *Radiother Oncol*. 2012 Sep;104(3):272-8. doi: 10.1016/j.radonc.2012.08.001. Epub 2012 Aug 30.
152. **Lee AWM***, Lin JC, Ng WT. Current Management of Nasopharyngeal Cancer. *Seminars in Radiat Oncol*. 2012 Jul;22(3):233-44. doi: 10.1016/j.semradonc.2012.03.008.
153. **Lee AWM***, Fee WE Jr, Ng WT, Chan LK. Nasopharyngeal Carcinoma: Salvage of Local Recurrence. *Oral Oncol*. 2012 Sep;48(9):768-74. doi: 10.1016/j.oraloncology.2012.02.017. Epub 2012 Mar 14.
154. Chan OSH, Yeung RMW, Hung AWM, Lee MCH, Chang ATY, Chan CCC, **Lee AWM**. Stereotactic Ablative Radiotherapy for Medically Inoperable Early Stage Lung Cancer: Early Outcomes. *HK Med J*. 2012 Oct;18(5):412-8.
155. Chan OSH, Lee MCH, Hung AWM, Chang ATY, Yeung RMW, **Lee AWM**. The Superiority of Hybrid-Volumetric Arc Therapy (VMAT) Technique over Double Arcs VMAT and 3D-Conformal Technique in the Treatment of Locally Advanced Non-Small Cell Lung Cancer – A Planning Study. *Radiother Oncol*. 2011 Nov;101(2):298-302. doi: 10.1016/j.radonc.2011.08.015. Epub 2011 Sep 8.
156. **Lee AWM***, Tung SY, Chan ATC, Chappell R, Fu YT, Lu TX, Tan T, Chua DTT, O'Sullivan B, Tung R, Ng WT, Leung TW, Leung SF, Yau S, Zhao C, Tan EH, Au GKH, Siu L, Fung KK, Lau WH. A Randomized Trial on Addition of Concurrent-Adjuvant Chemotherapy and/or Accelerated Fractionation for Locally-Advanced Nasopharyngeal Carcinoma. *Radiother Oncol*. 2011 Jan;98(1):15-22. doi: 10.1016/j.radonc.2010.09.023.
157. Chan SH, Cheung FMF, Ng WT, Choi CW; Cheung KN, Yiu KH, **Lee AWM**. Can the Analysis of ERCC1 Expression Contribute to Individualized Therapy in Nasopharyngeal Carcinoma? *Int J Radiat Oncol Biol Phys*. 2011 Apr 1;79(5):1414-20. doi: 10.1016/j.ijrobp.2009.12.072. Epub 2010 Jun 3.
158. Ng WT, Lee MCH, Hung WM, Choi CW, Lee KC, Chan OSH, **Lee AWM**. Clinical Outcomes and Patterns of Failure after Intensity-Modulated Radiotherapy for

- Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys*. 2011 Feb 1;79(2):420-8. doi: 10.1016/j.ijrobp.2009.11.024. Epub 2010 May 6.
159. Chang ATY, Ng WT, Law ALY, Ku KM, Lee MCH, **Lee AWM**. Adjuvant Chemoradiation for Resected Gastric Cancer: A 10-Year Experience. *Gastric Cancer*. 2011 Mar;14(1):63-71. doi: 10.1007/s10120-011-0011-y. Epub 2011 Feb 17.
 160. Choi CW, Lee MCH, Ng WT, Law LY, Yau TK, **Lee AWM**. An Analysis of the Efficacy of Serial Screening for Familial Nasopharyngeal Carcinoma Based on Markov Chain Models. *Familial Cancer*. 2011 Mar;10(1):133-9. doi: 10.1007/s10689-010-9397-7.
 161. **Lee AWM***, Tung SY, Ngan RKC, Chappell R, Chua DTT, Lu TX, Siu L, Tan T, Chan LK, Ng WT, Leung TW, Fu YT, Au GKH, Zhao C, O'Sullivan B, Tan EH, Lau WH. Factors Contributing to the Efficacy of Concurrent-Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: Combined Analyses of NPC-9901 And NPC-9902 Trials. *Eu J Cancer*. 2011 Mar;47(5):656-66. doi: 10.1016/j.ejca.2010.10.026. Epub 2010 Nov 26.
 162. Tse VC, Ng WT, Lee V, **Lee AWM**, Chua DTT, Chau J, McGhee SM. Cost-Analysis of XELOX and FOLFOX4 for Treatment of Colorectal Cancer to Assist Decision-Making on Reimbursement. *BMC Cancer*. 2011 Jul 9;11:288. doi: 10.1186/1471-2407-11-288.
 163. Yau TK, Choi CW, Ng E, Yeung R, Soong IS, **Lee AWM**. Delayed presentation of symptomatic breast cancers in Hong Kong: experience in a public cancer centre. *HK Med J*. 2010 Oct;16(5):373-7.
 164. Ng DCK, Wong SKH, Ng WT, **Lee AWM**, Li MKW. Impact of Adjuvant Chemoradiation for Adenocarcinoma of Stomach after Curative Gastrectomy in Chinese: A 7-Year Audit. *Surg Practice*. 2010; 14(3):85-91. <https://doi.org/10.1111/j.1744-1633.2010.00504.x>.
 165. Ng WT, Choi CW, Lee MCH, Law LY, Yau TK, **Lee AWM**. Outcomes of Nasopharyngeal Carcinoma Screening for High Risk Family Members in Hong Kong. *Familial Cancer*. 2010 Jun;9(2):221-8. doi: 10.1007/s10689-009-9296-y.
 166. **Lee AWM***, Tung SY, Chua DTT, Ngan RKC, Chappell R, Tung R, Siu L, Ng WT, Sze WK, Au GKH, Law SCK, O'Sullivan B, Yau TK, Leung TW, Au JSK, Sze WM, Choi CW, Fung KK, Lau JT, Lau WH. Randomized Trial of Radiotherapy Plus Concurrent-Adjuvant Chemotherapy vs Radiotherapy Alone for Regionally Advanced Nasopharyngeal Carcinoma. *J NCI*. 2010 Aug 4;102(15):1188-98. doi: 10.1093/jnci/djq258. Epub 2010 Jul 15.
 167. Chan OSH, Hung AWM, Lee MCH, Chang ATY, Yeung RMW, **Lee AWM**. The Superiority of Hybrid-Rapidarc Radiotherapy Technique in the Treatment of Advanced Non-Small Cell Lung Cancer: A Planning Study. *Int J Radiat Oncol Biol Phys*. 2010; 78(3):S814-S815. doi: <https://doi.org/10.1016/j.ijrobp.2010.07.1886>.
 168. Yau TK, Soong IS, Sze H, Choi CW, Yeung MW, Ng WT, **Lee AWM**. Trends and Patterns of Breast Conservation Treatment in Hong Kong: 1994-2007. *Int J Radiat Oncol Biol Phys*. 2009 May 1;74(1):98-103. doi: 10.1016/j.ijrobp.2008.07.066. Epub 2008 Dec 26.
 169. Chan SH, Ng WT, Kam KL, Lee MCH, Choi CW, Yau TK, **Lee AWM**, Chow SK. Sensorineural Hearing Loss after Treatment of Nasopharyngeal Carcinoma: A Longitudinal Analysis. *Int J Radiat Oncol Biol Phys*. 2009 Apr 1;73(5):1335-42. doi: 10.1016/j.ijrobp.2008.07.034. Epub 2008 Oct 14.
 170. **Lee AWM***, Ng WT, Hung WM, Choi CW, Tung R, Ling YH, Cheng PTC, Yau TK, Chang ATY, Leung SKC, Lee MCH, Bentzen SM. Major Late Toxicities after Conformal Radiotherapy for Nasopharyngeal Carcinoma – Patient and Treatment-Related Risk Factors.

- Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1121-8. doi: 10.1016/j.ijrobp.2008.05.023. Epub 2008 Aug 23.
171. Yau TK, Ng TY, Soong IS, Choi CW, Lam KO, Ng AWY, **Lee AWM**, Tung Y. Toxicity of Docetaxel Plus Cyclophosphamide as Adjuvant Therapy for Breast Cancer in Chinese Patients – The Hong Kong Experience. *Asia Pacific J Clin Oncol*. 2009; 5(2):123-128. <https://doi.org/10.1111/j.1743-7563.2009.01204.x> .
 172. Yau TK, Choi CW, Sze H, Soong IS, **Lee AWM**. Should Young Age be a Contraindication to Breast Conservation Treatment in Chinese Women? Twelve-Year Experience from A Public Cancer Centre in Hong Kong. *HK Med J*. 2009 Apr;15(2):94-9.
 173. Ng WT, Choi CW, Lee MCH, Chan SH, Yau TK, **Lee AWM**. Familial Nasopharyngeal Carcinoma in Hong Kong: Epidemiology and Implication in Screening. *Familial Cancer*. 2009;8(2):103-8. doi: 10.1007/s10689-008-9213-9. Epub 2008 Aug 26.
 174. Yau TK, Sze H, Soong I, Wong W, Chan K, Chang A, Lau K, **Lee AWM**. Surveillance Mammography after Breast Conservation Therapy in Hong Kong: Effectiveness and Feasibility of Risk-Adapted Approach. *Breast*. 2008 Apr;17(2):132-7. doi: 10.1016/j.breast.2007.08.001. Epub 2007 Oct 1.
 175. Yau TK, Sze H, Soong I, Hioe F, Khoo US, **Lee AWM**. HER2 Overexpression of Breast Cancers in Hong Kong: Prevalence and Concordance between Immunohistochemistry and In-Situ Hybridization Assays. *HK Med J*. 2008 Apr;14(2):130-5.
 176. Yau TK, Soong IS, Chan K, Chang A, Sze H, Yeung MW, Tung R, Lau S, **Lee AWM**. Evaluation of the Prognostic Value of 2005 St. Gallen Risk Categories for Operated Breast Cancers in Hong Kong. *Breast*. 2008 Feb;17(1):58-63. doi: 10.1016/j.breast.2007.06.007. Epub 2007 Sep 4.
 177. Ng WT, Chan SH, **Lee AWM**, Lau KY, Yau TK, Hung WM, Lee MCH, Choi CW. Parapharyngeal Extension of Nasopharyngeal Carcinoma: Still a Significant Factor in Era of Modern Radiotherapy? *Int J Radiat Oncol Biol Phys*. 2008 Nov 15;72(4):1082-9. doi: 10.1016/j.ijrobp.2008.02.006. Epub 2008 Apr 12.
 178. **Lee AWM***, Lau KY, Hung WM, Ng WT, Lee MCH, Choi CW, Chan CCC, Tung R, Cheng PTC, Yau TK. Potential Improvement of Tumor Control Probability by Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma. *Radiother Oncol*. 2008 May;87(2):204-10. doi: 10.1016/j.radonc.2008.02.003. Epub 2008 Mar 10.
 179. Yau TK, Soong IS, Chan K, Chan M, Cheung P, Lau HW, Chang ATY, **Lee AWM**. Clinical Outcome of Breast Conservation Therapy for Breast Cancer in Hong Kong: Prognostic Impact of Ipsilateral Breast Tumor Recurrence and 2005 St. Gallen Risk Categories. *Int J Radiat Oncol Biol Phys*. 2007 Jul 1;68(3):667-72. doi: 10.1016/j.ijrobp.2006.12.043. Epub 2007 Mar 26.
 180. Ng WT, **Lee AWM**, Kan WK, Chan J, Pang ESY, Yau TK, Lau KY. N-Staging by Magnetic Resonance Imaging for Patients with Nasopharyngeal Carcinoma: Pattern of Nodal Involvement by Radiological Levels. *Radiother Oncol*. 2007 Jan;82(1):70-5. doi: 10.1016/j.radonc.2006.11.010. Epub 2006 Dec 12.
 181. **Lee AWM***. Nasopharyngeal Cancer: Advances in Radiotherapy. *Int J Radiat Oncol Biol Phys*. 2007;69(2 Suppl):S115-7. doi: 10.1016/j.ijrobp.2007.05.042.
 182. **Lee AWM***. In Regards to Chen et al.: Experience in Fractionated Stereotactic Body Radiation Therapy Boost for Newly Diagnosed Nasopharyngeal Carcinoma (*IJROBP* 2006; 66:1408-1414). *Int J Radiat Oncol Biol Phys*. 2007 Aug 1;68(5):1584-5; author reply 1585. doi: 10.1016/j.ijrobp.2007.03.015.

183. Choi CY, Ng WT, Chang ATY, Soong IS, **Lee AWM**. Analysis of Cervical Cancer in Chinese Patients Treated with Chemoradiation or Radiotherapy Alone. *J HK College of Radiologists*. 2007;10:51-8.
184. Yau TK, **Lee AWM**, Wong DHM, Pang ESY, Ng WT, Yeung RMW, Soong IS. Treatment of Stage IV (A-B) Nasopharyngeal Carcinoma by Induction-Concurrent Chemoradiotherapy and Accelerated Fractionation: Impact of Chemotherapy Schemes. *Int J Radiat Oncol Biol Phys*. 2006 Nov 15;66(4):1004-10. doi: 10.1016/j.ijrobp.2006.06.016.
185. Yau TK, Chan K, Chan M, Lau HW, Soong IS, Cheung P, Chang ATY, **Lee AWM**. Wide Local Excision and Radiotherapy for the Treatment of Ductal Carcinoma in Situ of The Breast: The Hong Kong Experience. *Clin Oncol*. 2006 Aug;18(6):447-52. doi: 10.1016/j.clon.2006.04.003.
186. **Lee AWM***, Tung SY, Chan ATC, Chappell R, Fu YT, Lu TX, Tan T, Chua DTT, O'Sullivan B, Xu SL, Pang ESY, Sze WM, Leung TW, Kwan WH, Chan PTM, Liu XF, Tan EH, Sham JST, Siu L, Lau WH. Preliminary Results of A Randomized Study (NPC-9902 Trial) on Therapeutic Gain by Concurrent Chemotherapy and/or Accelerated Fractionation for Locally Advanced Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys*. 2006 Sep 1;66(1):142-51. doi: 10.1016/j.ijrobp.2006.03.054.
187. Teo PML, Leung SF, Tung SY, Zee B, Sham JST, **Lee AWM**, Lau WH, Kwan WH, Leung TW, Chua D, Sze WM, Au JSK, Yu KH, O SK, Kwong D, Yau TK, Law SCK, Sze WK, Au G, Chan ATC. Dose-Response Relationship of Nasopharyngeal Carcinoma above Conventional Tumorcidal Level: A Study by The Hong Kong Nasopharyngeal Carcinoma Study Group (HKNPCSG). *Radiother Oncol*. 2006 Apr;79(1):27-33. doi: 10.1016/j.radonc.2006.03.012. Epub 2006 Apr 19.
188. Yau TK, **Lee AWM**, Wong DHM, Yeung RMW, Chan EWK, Ng WT, Tong M, Soong IS. Induction Chemotherapy with Cisplatin and Gemcitabine followed by Accelerated Radiotherapy and Concurrent Cisplatin in Patients with Stage IV (A-B) Nasopharyngeal Carcinoma. *Head & Neck*. 2006 Oct;28(10):880-7. doi: 10.1002/hed.20421.
189. Lee MCH, **Lee AWM**, Ling YH, Pang E, Ng WT, Hung AWM, Leung SKC, Chan DWI, Law ALY, Yau TK. Fitting of Biological Parameters for Tumor Control Probability of Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys*. 2006; 66(3):S417-S418.
190. **Lee AWM***. A Tribute to the Father of Radiology and Oncology in Hong Kong – The Legend of John H. C. Ho, MD Obituary. *Int J Radiat Oncol Biol Phys*. 2006 Jan 1;64(1):1-2. doi: 10.1016/j.ijrobp.2005.08.026.
191. **Lee AWM***, Lau WH, Tung SY, Chua DTT, Chappell R, Xu L, Siu L, Sze WM, Leung TW, Sham JST, Ngan RKC, Law SCK, Yau TK, Au JSK, O'Sullivan B, Pang ESY, O SK, Au GKH, Lau JT. Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by The Hong Kong Nasopharyngeal Cancer Study Group. *JCO*. 2005 Oct 1;23(28):6966-75. doi: 10.1200/JCO.2004.00.7542.
192. **Lee AWM***, Yau TK, Wong DHM, Chan EWK, Yeung RMW, Ng WT, Tong M, Soong IS, Sze WM. Treatment of Stage IV (A-B) Nasopharyngeal Carcinoma by Induction-Concurrent Chemoradiotherapy and Accelerated Fractionation. *Int J Radiat Oncol Biol Phys*. 2005 Dec 1;63(5):1331-8. doi: 10.1016/j.ijrobp.2005.05.061.
193. **Lee AWM***, Sze WM, Au JSK, Leung SF, Leung TW, Chua DTT, Zee BCY, Law SCK, Teo PML, Tung SY, Kwong DLW, Lau WH. Treatment Results for Nasopharyngeal

- Carcinoma in the Modern Era: The Hong Kong Experience. *Int J Radiat Oncol Biol Phys*. 2005 Mar 15;61(4):1107-16. doi: 10.1016/j.ijrobp.2004.07.702.
194. Yu KH, Leung SF, Tung SY, Zee B, Chua DTT, Sze WM, Law SCK, Kam MKM, Leung TW, Sham JST, **Lee AWM**, Au JSK, Hui EP, Sze WK, Cheng ACK, Yau TK, Ngan RKC, Wong FCS, Au GKH, Chan ATC. Survival Outcome of Patients with Nasopharyngeal Carcinoma with First Local Failure: A Study by the Hong Kong Nasopharyngeal Carcinoma Study Group. *Head & Neck*. 2005 May;27(5):397-405. doi: 10.1002/hed.20161.
 195. Sze WM, **Lee AWM**. In Regards to Sze et al.: Primary Tumor Volume of Nasopharyngeal Carcinoma: Prognostic Significance for Local Control (*IJROBP* 2004: 59:21-27) - Response. *Int J Radiat Oncol Biol Phys*. 2005; 61(2):629-629.
 196. Le QT, Jones CD, Yau TK, Shirazi HA, Wong PH, Thomas EN, Patterson BK, **Lee AWM**, Zehnder JL. A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels In Patients with Nasopharyngeal Carcinoma. *Cancer Research*. 2005 Aug 15;11(16):5700-7. doi: 10.1158/1078-0432.CCR-05-0648.
 197. Ng WT, Yau TK, Yung RWH, Sze WM, Tsang AHL, Law ALY, **Lee AWM**. Screening for Family Members of Patients with Nasopharyngeal Carcinoma. *IJC*. 2005 Mar 1;113(6):998-1001. doi: 10.1002/ijc.20672.
 198. **Lee AWM***. A Tribute to the Emperor Extraordinaire: The Legend of John H. C. Ho. *J HK College of Radiologists*. 2005; 8:117-120.
 199. Yau TK, Sze WM, **Lee AWM**, Yeung MW, Leung KC, Hung WM, Chan WI. Effectiveness of Brachytherapy and Fractionated Stereotactic Radiotherapy Boost for Persistent Nasopharyngeal Carcinoma. *Head & Neck*. 2004 Dec;26(12):1024-30. doi: 10.1002/hed.20093.
 200. Soong IS, Yau TK, Ho CM, Lim BH, Leung S, Yeung RMW, Sze WM, **Lee AWM**. Post-Mastectomy Radiotherapy after Immediate Autologous Breast Reconstruction in Primary Treatment of Breast Cancers. *Clin Oncol*. 2004 Jun;16(4):283-9. doi: 10.1016/j.clon.2004.01.007.
 201. Sze WM, **Lee AWM**, Yau TK, Yeung RMW, Lau KY, Leung SKC, Hung AWM, Lee MCH, Chappell R, Chan K. Primary Tumor Volume of Nasopharyngeal Carcinoma: Prognostic Significance for Local Control. *Int J Radiat Oncol Biol Phys*. 2004 May 1;59(1):21-7. doi: 10.1016/j.ijrobp.2003.10.027.
 202. Sze WM, **Lee AWM**, Tong M, Ng C, Soong I, Chan K, Yeung R, Yau TK. Preliminary Experience on Treating Advanced Nasopharyngeal Carcinoma (NPC) Affecting/Abutting Neurological Structures with Induction Chemotherapy followed by Concurrent Chemo-Radiation with Accelerated Fractionation. *JCO*. 2004; 22(14):494S-494S. doi: 10.1200/jco.2004.22.90140.5525.
 203. **Lee AWM***, Au JSK, Teo PML, Leung TW, Chua DTT, Sze WM, Zee BCY, Law SCK, Leung SF, Tung SY, Kwong DLW, Lau WH. Staging of Nasopharyngeal Carcinoma: Suggestions for Improving the Current UICC/AJCC Staging System. *Clin Oncol*. 2004 Jun;16(4):269-76. doi: 10.1016/j.clon.2004.01.008.
 204. Lau KY, Kan WK, Sze WM, **Lee AWM**, Yau TK, Tan LTH, Chan PO. Accuracy of Nasopharyngeal Carcinoma Staging by Magnetic Resonance Imaging. *Aust Radiol*. 2004 Mar;48(1):14-6. doi: 10.1111/j.1440-1673.2004.01234.x.
 205. Lau KY, Kan WK, Sze WM, **Lee AWM**, Chan JKW, Yau TK, Yeung RM, Tan LTH, Chan PO, Lee ASL. Magnetic Resonance for T-Staging of Nasopharyngeal Carcinoma - The Most

- Informative Pair of Sequences. *Jpn J Clin Oncol*. 2004 Apr;34(4):171-5. doi: 10.1093/jjco/hyh033.
206. **Lee AWM***, Foo W, Mang O, Sze WM, Chappell R, Lau WH, Ko WM. Changing Epidemiology of Nasopharyngeal Carcinoma in Hong Kong over a 20-Year Period (1980-99): An Encouraging Reduction in both Incidence and Mortality. *IJC*. 2003 Feb 20;103(5):680-5. doi: 10.1002/ijc.10894.
 207. **Lee AWM***. Contribution of Radiotherapy to Function Preservation and Cancer Outcome in Primary Treatment of Nasopharyngeal Carcinoma. *World J Surg*. 2003 Jul;27(7):838-43. doi: 10.1007/s00268-003-7109-2.
 208. Yau TK, Lau Y, Kong J, Yeung MW, Chan M, Sze WM, Cheung P, Lim BH, **Lee AWM**. Breast Conservation Treatment in Hong Kong – Early Results of 203 Patients: Retrospective Study. *HK Med J*. 2002 Oct;8(5):322-8.
 209. **Lee AWM***, Kwong DLW, Leung SF, Tung SY, Sze WM, Sham JST, Teo PML, Leung TW, Wu PM, Chappell R, Peters LJ, Fowler JF. Factors Affecting Risk of Symptomatic Temporal Lobe Necrosis: Significance of Fractional Dose and Treatment Time. *Int J Radiat Oncol Biol Phys*. 2002 May 1;53(1):75-85. doi: 10.1016/s0360-3016(02)02711-6.
 210. Wai HPS, Yeung RMW, Sze WM, Yau TK, **Lee AWM**. A Review of Superior Vena Cava Obstruction in Hong Kong Chinese Patients. *J HK College of Radiologists*. 2001; 4:143-145.
 211. **Lee AWM***, Sze WM, Yau TK, Yeung RMW, Chappell R, Fowler JF. Retrospective Analysis on Treating Nasopharyngeal Carcinoma with Accelerated Fractionation (6 Fractions per Week) in Comparison with Conventional Fractionation (5 Fractions per Week.): Report on 3-Year Tumor Control and Normal Tissue Toxicity. *Radiother Oncol*. 2001 Feb;58(2):121-30. doi: 10.1016/s0167-8140(00)00312-1.
 212. Lau KY, Fung WT, Chan PO, Sze WM, **Lee AWM**, Yau TK. MRI of the Hypothalamus and Pituitary Gland in Patients with Hyperprolactinaemia following Radiotherapy for Nasopharyngeal Carcinoma. *Singapore Med J*. 2001 Sep;42(9):406-9.
 213. Yu CLM, Fielding R, Chan CLW, Tse VKC, Choi PHK, Choy DTK, O SK, **Lee AWM**, Sham JST. Measuring Quality of Life of Chinese Cancer Patients – A Validation of the Chinese Version of the Functional Assessment of Cancer Therapy-General (Fact-G) Scale. *Cancer*. 2000 Apr 1;88(7):1715-27.
 214. Wai HPS, Yau TK, Sze WM, Yeung MW, **Lee AWM**. Quadruple Primary Neoplasms in A 27-Year-Old Woman. *Hospital Med*. 2000 Feb;61(2):138-9. doi: 10.12968/hosp.2000.61.2.2401.
 215. Wai HPS, Yau TK, Sze WM, Yeung MW, Hioe F, **Lee AWM**. Metastatic Tumour of the Tunica Vaginalis Testis from Carcinoma of The Stomach. *Int J Clin Practice*. 2000 Dec;54(10):685-6.
 216. **Lee AWM***, Foo W, Law SCK, Peters LJ, Poon YF, Chappell R, Sze WM, Tung SY, Lau WH, Ho JHC. Total Biological Effect on Late Reactive Tissues following Reirradiation for Recurrent Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys*. 2000 Mar 1;46(4):865-72. doi: 10.1016/s0360-3016(99)00512-x.
 217. Sze WM, **Lee AWM**. Radiotherapy and Chemotherapy for Cervical Cancer. *J HK College of Radiologists*. 1999; 2(2):76-86.
 218. **Lee AWM***, Sze WM, Fowler JF, Chappell R, Leung SF, Teo P. Caution on the Use of Altered Fractionation for Nasopharyngeal Carcinoma. *Radiother Oncol*. 1999 Sep;52(3):207-11. doi: 10.1016/s0167-8140(99)00116-4.

219. **Lee AWM***, Foo W, Law SCK, Poon YF, Sze WM, Tung SY, Chappell R, Lau WH, Ho JHC. Recurrent Nasopharyngeal Carcinoma: The Puzzles of Long Latency. *Int J Radiat Oncol Biol Phys*. 1999 Apr 1;44(1):149-56. doi: 10.1016/s0360-3016(98)00524-0.
220. **Lee AWM***, Foo W, Law SCK, Poon YF, O SK, Tung SY, Sze WM, Chappell R, Lau WH, Ho JHC. Staging of Nasopharyngeal Carcinoma: From Ho's to the New UICC System. *IJC*. 1999 Apr 20;84(2):179-87. doi: 10.1002/(sici)1097-0215(19990420)84:2<179::aid-ijc15>3.0.co;2-6.
221. **Lee AWM***, Ko WM, Foo W, Choi P, Tung Y, Sham J, Cheng B, Au G, Lau WH, Choy D, O SK, Sze WM, Tse KC, Law CK, Teo P, Yau TK, Kwan WH. Nasopharyngeal Carcinoma: Time Lapse before Diagnosis and Treatment. *HK Med J*. 1998 Jun;4(2):132-136.
222. **Lee AWM***, Foo W, Chappell R, Fowler JF, Sze WM, Poon YF, Law SCK, Ng SH, O SK, Tung SY, Lau WH, Ho JHC. Effect of Time, Dose, and Fractionation on Temporal Lobe Necrosis following Radiotherapy for Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys*. 1998 Jan 1;40(1):35-42. doi: 10.1016/s0360-3016(97)00580-4.
223. Cheung F, Pang SW, Hioe F, Cheung KN, **Lee AWM**, Yau TK. Nasopharyngeal Carcinoma in Situ: Two Cases of an Emerging Diagnostic Entity. *Cancer*. 1998 Sep 15;83(6):1069-73.
224. **Lee AWM***, Foo W, Law SCK, Poon YF, Sze WM, Tung SY, Lau WH. Reirradiation for Recurrent Nasopharyngeal Carcinoma: Factors Affecting the Therapeutic Ratio and Ways for Improvement. *Int J Radiat Oncol Biol Phys*. 1997 Apr 1;38(1):43-52. doi: 10.1016/s0360-3016(97)00244-7.
225. **Lee AWM***, Foo W, Law SCK, Poon YF, Sze WM, O SK, Tung SY, Lau WH. Nasopharyngeal Carcinoma: Presenting Symptoms and Duration before Diagnosis. *HK Med J*. 1997 Dec;3(4):355-361.
226. **Lee AWM***, Foo W, Law SCK, O SK, Tung SY, Sze WM, Lau WH. N-Staging of Nasopharyngeal Carcinoma: Discrepancy between UICC/AJCC and Ho's System. *Clin Oncol*. 1996;8(3):155-9. doi: 10.1016/s0936-6555(96)80039-2.
227. **Lee AWM***, Foo W, Poon YF, Law SCK, Chan DKK, O SK, Tung SY, Ho JHC. Staging of Nasopharyngeal Carcinoma: Evaluation of N-Staging by Ho and UICC/AJCC System. *Clin Oncol*. 1996;8(3):146-54. doi: 10.1016/s0936-6555(96)80038-0.
228. **Lee AWM***, Chan DKK, Fowler JF, Poon YF, Foo W, Law SCK, O SK, Tung SY, Chappell R. Effect of Time, Dose and Fractionation on Local Control of Nasopharyngeal Carcinoma. *Radiother Oncol*. 1995 Jul;36(1):24-31. doi: 10.1016/0167-8140(95)01579-6.
229. Wong KF, Chan JKC, Li LPK, Yau TK, **Lee AWM**. Primary Cutaneous Plasmacytoma: Report of Two Cases and Review of the Literature. *Am J Dermatopath*. 1994 Aug;16(4):392-7. doi: 10.1097/00000372-199408000-00006.
230. **Lee AWM***, Chan DKK, Fowler JF, Poon YF, Law SCK, Foo W, Tung SY, Cheung FK, Ho JHC, Chappell R. T-1 Nasopharyngeal Carcinoma – The Effect of Waiting Time on Tumor Control. *Int J Radiat Oncol Biol Phys*. 1994 Dec 1;30(5):1111-7. doi: 10.1016/0360-3016(94)90317-4.
231. Tsang WYW, Chan JKC, Loo KT, Wong KF, **Lee AWM**. Granulomatous Slack Skin. *Histopath*. 1994; 25(1):49-55. <https://doi.org/10.1111/j.1365-2559.1994.tb00597.x>.
232. Chan JKC, Tsang WYW, Ng CS, Tang SK, Yu HC, **Lee AWM**. Follicular Dendritic Cell Tumors of the Oral Cavity. *Am J Surg Path*. 1994 Feb;18(2):148-57. doi: 10.1097/00000478-199402000-00004.

233. Yau TK, Yiu HY, **Lee AWM**. Case Report: Central Pontine Myelinolysis after Cisplatin-Containing Chemotherapy for Nasopharyngeal Carcinoma. *Clin Oncol*. 1993;5(6):395-6. doi: 10.1016/s0936-6555(05)80096-2.
234. Leung TW, **Lee AWM**, Chan DKK. Definitive Radiotherapy for Carcinoma of the Oral Tongue. *Acta Oncologica*. 1993;32(5):559-64. doi: 10.3109/02841869309096118.
235. **Lee AWM***, Law SCK, Foo W, Poon YF, Cheung FK, Chan DKK, Tung SY, Thaw M, Ho JHC. Retrospective Analysis of Patients with Nasopharyngeal Carcinoma Treated during 1976-1985 - Survival After Local Recurrence. *Int J Radiat Oncol Biol Phys*. 1993 Aug 1;26(5):773-82. doi: 10.1016/0360-3016(93)90491-d.
236. **Lee AWM***, Law SCK, Foo W, Poon YF, Chan DKK, O SK, Tung SY, Cheung FK, Thaw M, Ho JHC. Nasopharyngeal Carcinoma - Local-Control by Megavoltage Irradiation. *Brit J Radiol*. 1993 Jun;66(786):528-36. doi: 10.1259/0007-1285-66-786-528.
237. **Lee AWM***, Ng SH, Tse VKC, Chiu HM, Thaw M. Bilateral Temporal Lobectomy for Necrosis Induced by Radiotherapy for Nasopharyngeal Carcinoma. *Acta Oncologica*. 1993;32(3):343-4. doi: 10.3109/02841869309093607.
238. **Lee AWM***. Decision-Making for Reirradiation of Nasopharyngeal Carcinoma - Response. *Int J Radiat Oncol Biol Phys*. 1993; 26(5):907-907.
239. **Lee AWM***, Law SCK, Ng SH, Chan DKK, Poon YF, Foo W, Tung SY, Cheung FK, Ho JHC. Retrospective Analysis of Nasopharyngeal Carcinoma Treated during 1976-1985 - Late Complications following Megavoltage Irradiation. *Brit J Radiol*. 1992 Oct;65(778):918-28. doi: 10.1259/0007-1285-65-778-918.
240. **Lee AWM***, Poon YF, Foo W, Law SCK, Cheung FK, Chan DKK, Tung SY, Thaw M, Ho JHC. Retrospective Analysis of 5037 Patients with Nasopharyngeal Carcinoma Treated during 1976-1985 - Overall Survival and Patterns of Failure. *Int J Radiat Oncol Biol Phys*. 1992;23(2):261-70. doi: 10.1016/0360-3016(92)90740-9.
241. **Lee AWM***, Cheng LOC, Ng SH, Tse VKC, Au GKH, O SK, Poon YF. Magnetic-Resonance-Imaging in the Clinical- Diagnosis of Late Temporal-Lobe Necrosis following Radiotherapy for Nasopharyngeal Carcinoma. *Clin Oncol*. 1990 Jul;42(1):24-31. doi: 10.1016/s0009-9260(05)81617-4.
242. **Lee AWM***, Sham JST, Poon YF, Ho, JHC. Treatment of Stage-I Nasopharyngeal Carcinoma - Analysis of the Patterns of Relapse and the Results of Withholding Elective Neck Irradiation. *Int J Radiat Oncol Biol Phys*. 1989 Dec;17(6):1183-90. doi: 10.1016/0360-3016(89)90524-5.
243. **Lee AWM***, Ng SH, Ho JHC, Tse VKC, Poon YF, Tse CCH, Au GKH, Lau WH, Foo WWL. Clinical Diagnosis of Late Temporal-Lobe Necrosis following Radiation-Therapy for Nasopharyngeal Carcinoma. *Cancer*. 1988 Apr 15;61(8):1535-42. doi: 10.1002/1097-0142(19880415)61:8<1535:aid-cncr2820610809>3.0.co;2-e.
244. Lam KSL, Ho JHC, **Lee AWM**, Tse VKC, Chan PK, Wang C, Ma JTC, Yeung RTT. Symptomatic Hypothalamic-Pituitary Dysfunction in Nasopharyngeal Carcinoma Patients following Radiation-Therapy - A Retrospective Study. *Int J Radiat Oncol Biol Phys*. 1987 Sep;13(9):1343-50. doi: 10.1016/0360-3016(87)90227-6.

Presentations at Academic Conferences - Invited Lectures

International Conferences /Overseas Institutes

1. Staging – UICC Global Advisory Group. Conference of Russian Oncologic Association, 29-30 October 2021, Online.
2. Clinical oncology: The global impact of COVID-19 – an update two years on. RCR Learning Live 2021, 7 October 2021, Virtual Platform.
3. Fostering Collaboration to achieve Global Unification in Cancer Staging. XI Congress of Oncologists of Russia, 13 May 2021, Virtual Platform.
4. Advocating occupational safety in China. International Society for Quality in Health Care (ISQua) – International Hospital Federation (IHF) Virtual Conference, 23 February 2021.
5. Panelist for the 3rd FARO webinar 2021 “Hypofractionated radiotherapy in Head and Neck Cancer during the Covid-19 pandemic situation”, Federation of Asian Organizations for Radiation Oncology (FARO), 16 January 2021.
6. What is the Optimal Way to Sequence Chemotherapy for Nasopharynx Cancer and Which Chemotherapy to Use. ASTRO 62nd Annual Meeting 2020, 24-28 October 2020, Virtual Platform.
7. The impact of COVID-19 – Shenzhen. RCR 2020 Digital Learning Programme, 21 September - 9 October 2020.
8. My Journey in Research on Nasopharyngeal Cancer. Plenary Speaker for the 1st Malaysian Association for Cancer Research (MACR) Scientific Conference, 3-4 December 2019, Malaysia.
9. The Strengths and Weaknesses of EBV-DNA as a biomarker for Nasopharyngeal Cancer. The 6th Asian Society of Head & Neck Oncology 2019, 27-30 March 2019, Seoul, South Korea.
10. International Consensus of CTV Delineation. The 6th Asian Society of Head & Neck Oncology 2019, 27-30 March 2019, Seoul, South Korea.
11. IAEA Project (E33039): to Improve Outcome for NPC – Recommendations on Dose Fractionation & Imaging. Second Research Coordination Meeting on Improving Radiotherapy Treatment Planning for Patients with Nasopharyngeal Carcinoma in Low- and Middle-Income Countries, the International Atomic Energy Agency (IAEA), 4-6 March 2019, Vienna, Austria.
12. IAEA Project (E33039): to Improve Outcome for NPC – Recommendations on CTV Contouring, Dose Prioritization & Constraints. Second Research Coordination Meeting on Improving Radiotherapy Treatment Planning for Patients with Nasopharyngeal Carcinoma in Low- and Middle-Income Countries, the International Atomic Energy Agency (IAEA), 4-6 March 2019, Vienna, Austria.
13. IAEA Project (E33039): to Improve Outcome for NPC – Clinical Study on quality of Treatment Preliminary Data from 1st Phase (Baseline Assessment). Second Research Coordination Meeting on Improving Radiotherapy Treatment Planning for Patients with Nasopharyngeal Carcinoma in Low- and Middle-Income Countries, the International Atomic Energy Agency (IAEA), 4-6 March 2019, Vienna, Austria.
14. IAEA Project (E33039): to Improve Outcome for NPC – Background & Design of Study. Second Research Coordination Meeting on Improving Radiotherapy Treatment Planning for Patients with Nasopharyngeal Carcinoma in Low- and Middle-Income Countries, the International Atomic Energy Agency (IAEA), 4-6 March 2019, Vienna, Austria.

15. Emerging Radiotherapy Advances in Nasopharyngeal Cancer – What to Expect in the Next Decade? Nasopharyngeal Cancer Workshop 2019, The HEAD Foundation Singapore, 25-26 January 2019, Singapore.
16. The Battle against Nasopharyngeal Cancer. The 1st International Conference of Nasopharyngeal Carcinoma 2018, University Sumatera Utara, 6-7 December 2018, Indonesia.
17. Evaluation of the global pattern of cancer survival and the correlation with healthcare expenditures. UICC, World Cancer Congress 2018, 30 September – 4 October 2018, Kuala Lumpur.
18. Landscape of Nasopharyngeal Carcinoma Current Management of Loco-Regional Disease. Head and Neck Steering Committee (HNSC) Nasopharyngeal Cancer (NPC) Clinical Trials Planning Meeting (CTPM), 27-28 January 2018, Phoenix, USA.
19. 10-Year Outcome on the Efficacy and Late Toxicities Attributed to the Addition of Concurrent-Adjuvant Chemotherapy for Stage III-IVB Nasopharyngeal Carcinoma (Combined Analyses of the NPC-9901 and NPC-9902 Trials). ASTRO 2017 Annual Meeting, 24-27 September 2017, San Diego, USA.
20. Cancer classifications guiding patient care - China and GAG perspective on staging. World Cancer Congress, 31 October- 3 November 2016, Paris, France.
21. The Fight against Cancer in Hong Kong & our Contribution to the Asia-Pacific Region. World Cancer Congress, 31 October- 3 November 2016, Paris, France.
22. Nasopharyngeal Cancer. The AHNS International Conference on Head and Neck Cancer, 16-20 Jul 2016; Seattle, USA.
23. Instructional Courses 1 - Nasopharynx Cancer Management 2016. The AHNS International Conference on Head and Neck Cancer, 16-20 July 2016; Seattle, USA.
24. Nasopharyngeal Carcinoma - Case Discussion. Multidisciplinary Teaching Course on “Management of Head & Neck Cancer,” by ESTRO School, 14-17 June 2015, Beijing, China.
25. Management of Nasopharyngeal Carcinoma. Multidisciplinary Teaching Course on “Management of Head & Neck Cancer,” by ESTRO School, 14-17 June 2015, Beijing, China.
26. Global Pattern of Nasopharyngeal Cancer: Correlation of Outcome with Access to Radiotherapy. The 7th International Biannual Symposium on Nasopharyngeal Carcinoma, 4 – 6 June 2015, Yogyakarta, Indonesia.
27. Nasopharyngeal Cancer – Global Pattern & Lessons Learned from Hong Kong. Wharton Lecturer 2015. The 17th Annual Wharton / Elia Day Conference, 15 May 2015, Toronto, Canada.
28. Promoting TNM-Stage Use and Ensuring Stage is Globally Relevant. The 2014 World Cancer Congress, 3-6 December 2014, Melbourne, Australia.
29. Technical Meeting on Genetic Characteristics and Response to Radiation Therapy of Nasopharyngeal Carcinoma in North Africa and China. International Atomic Energy Agency (Project No:325-E3-TM-47712), Vienna, 14-17 October, 2014.
30. Management of primary and recurrent nasopharyngeal cancer. The 5th World Congress of International Federation of Head and Neck Oncologic Societies & American Head and Neck Society, 26-30 July 2014, New York, U.S.A.
31. Treatment of Recurrent Nasopharyngeal Cancer. The 24th Conference of the Scandinavian Society for Head and Neck Oncology, 20-21 April 2014, Stockholm, Sweden.
32. Nasopharyngeal Cancer - An Overview. The 24th Conference of the Scandinavian Society for Head and Neck Oncology, 20-21 April 2014, Stockholm, Sweden.

33. Role of induction chemotherapy in the nasopharyngeal carcinoma. 17th European Cancer Congress, 30 September - 1 October 2013, Amsterdam, Netherlands.
34. Contouring Course on IMRT for Nasopharyngeal Cancer. The 6th International Symposium on Nasopharyngeal Carcinoma, 20-22 June 2013, Istanbul, Turkey.
35. Impact of IMRT on Management of Nasopharyngeal Cancer. The 6th International Symposium on Nasopharyngeal Carcinoma, 20-22 June 2013, Istanbul, Turkey.
36. The Challenges of Constructing a National Staging Strategy: An Asian Perspective. The UICC World Cancer Congress, 27 – 30 August 2012, Montréal, Canada.
37. Nasopharyngeal Cancer - Radiation Therapy: Current State. The 8th International Conference on Head and Neck Cancer, 20 – July 25, 2012, Toronto, Canada.
38. Battle against nasopharyngeal cancer (Award Lecture for Honorary Member of ESTRO). ESTRO 31, 9-13 May 2012, Barcelona, Spain.
39. Nasopharyngeal Cancer: Hong Kong Experience. The 2011 Academic Conference of TASTRO & 1st Annual Meeting of TAROS, 26-27 November 2011, Taiwan.
40. Nasopharyngeal Cancer – How I Treat It (Instructional Course). The 3rd World Congress of the International Academy of Oral Oncology, 14-17 July 2011, Singapore.
41. Management of Recurrent Nasopharyngeal Cancer – Challenges for All. The 5th International Symposium on Nasopharyngeal Carcinoma, 20-22 June 2011, Malaysia
42. Re-irradiation in Nasopharyngeal Cancer. The 29th Annual Meeting, European Society for Therapeutic Radiology and Oncology, 12-16 September 2010, Barcelona, Spain.
43. Management of Nasopharyngeal Cancer (Instructional Course). The 4th World Congress of International Federation of Head and Neck Oncologic Societies, 15-19 June 2010, Seoul, Korea.
44. Overview of Clinical Trials on Concurrent Chemoradiotherapy for Nasopharyngeal Cancer. The 4th World Congress of International Federation of Head and Neck Oncologic Societies, 15-19 June 2010, Seoul, Korea.
45. Nasopharyngeal Cancer – Unique Challenges. The 16th Hong Kong International Cancer Congress. 4-6 November 2009, Hong Kong.
46. Opportunities for Collaborative Researches on Nasopharyngeal Carcinoma. The 4th International Symposium on Nasopharyngeal Carcinoma, 18-20 June 2009, Marrakech, Morocco.
47. Overview of Clinical Trials in Nasopharyngeal Cancer. Asian Oncology Summit (AOS) 2009, 3-5 April 2009, Singapore.
48. Nasopharyngeal Cancer: Unique Opportunities (Gilbert H. Fletcher Distinguished Professor Lecture). The 4th International Conference on Translational Research and Pre-Clinical Strategies in Radiation Oncology, 11-13 March 2009, Geneva, Switzerland.
49. Overview of collaborative trials in Hong Kong. First Hong Kong Australia Scientific Meeting of Head and Neck Oncology, 15 November 2008, Hong Kong.
50. Update on Chemoradiation for NPC. The 15th Hong Kong International Cancer Congress, 5th Annual Meeting of Centre for Cancer Research, 12-14 November 2008, Hong Kong.
51. Advances in the management of nasopharyngeal cancer. The 8th Princess Margaret Hospital Conference Developments in Cancer Management: Conquering Cancer in our Lifetime, 16-18 October 2008, Toronto, Ontario, Canada.
52. Nasopharyngeal Cancer (Educational Course). The 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology Meeting, 21-25 September 2008, Boston, U.S.A.

53. State of the art in Nasopharyngeal Cancer Treatment. International Union against Cancer, UICC World Cancer Congress, 27-32 August 2008, Geneva, Switzerland.
54. Nasopharyngeal Cancer (Educational Course). The 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology Meeting, 28 October – 1 November 2007, Los Angeles, U.S.A.
55. Nasopharyngeal Cancer: Fascinating achievements and new challenges. East-West Symposium on Nasopharyngeal Carcinoma, 30 July – 2 August 2007, Sunshine Coast, Australia.
56. Nasopharyngeal Cancer: Advances in Radiotherapy. Multidisciplinary Head and Neck Cancer Symposium, 18-20 January 2007, Palm Springs, U.S.A.
57. Combined modality treatment for nasopharyngeal carcinoma. 5th Shanghai International Conference on Radiation Oncology, 18-21 November 2006, Shanghai, China.
58. The Hong Kong story in the fight against nasopharyngeal cancer. The 11th Asian Oceanian Congress of Radiology, 6-9 August 2006, Hong Kong, China.
59. Management for nasopharyngeal cancer (Education Lecture). The 13th Annual Meeting, European Cancer Conference, 31 October – 3 November 2005, Paris, France.
60. Preliminary results of a prospective randomized study (NPC-9902 Trial) on the therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. East-West Symposium on Nasopharyngeal Carcinoma, 16-18 June 2005, Toronto, Canada.
61. Chemoradiation for NPC Patients. The 11th Hong Kong International Cancer Congress, 10-12 November 2004, Hong Kong.
62. Altered fractionation for nasopharyngeal carcinoma. The 2004 Symposium on Radiation Oncology, 8-10 April 2004, Shanghai, China.
63. Concurrent chemotherapy using cisplatin-based regimes for nasopharyngeal carcinoma. The 10th Hong Kong International Cancer Congress, 19-21 November 2003, Hong Kong.
64. Overview of new treatment strategies for nasopharyngeal carcinoma. The 2003 International and 7th National Head & Neck Cancer Congress, 7-11 November 2003, Guangzhou, China.
65. Altered fractionation for NPC – benefits and harms. UICC NPC Workshop 2003 and the 4th International UICC Symposium on Nasopharyngeal Carcinoma, 14-16 February 2003, Hong Kong.
66. Review of the AJCC/UICC 1997 Staging System for nasopharyngeal carcinoma – The Hong Kong (Pamela Youde Nethersole Eastern Hospital) experience. The 4th International UICC Symposium on Nasopharyngeal Carcinoma, 14-16 February 2003, Hong Kong.
67. Treatment strategies – The Hong Kong (Pamela Youde Nethersole Eastern Hospital) experience. The 10th ASEAN ORL Head and Neck Surgery Congress, 27-29 January 2003, Darussalam, Brunei.
68. Staging of nasopharyngeal carcinoma – critical review of the present AJCC/UICC system. The 10th ASEAN ORL Head and Neck Surgery Congress, 27-29 January 2003, Darussalam, Brunei.
69. Epidemiology of NPC – the world and local trends. The 10th ASEAN ORL Head & Neck Surgery Congress, 27-29 January 2003, Darussalam, Brunei.
70. Strategies for improving radiotherapy for nasopharyngeal carcinoma. The 4th Shanghai International Conference on Radiation Oncology, 20-22 May 2002, Shanghai, China.
71. Recent advances in management of nasopharyngeal carcinoma. The 16th Asia Pacific Cancer Conference, 18-21 November 2001, Manila, Philippines.

72. Developments in management of nasopharyngeal carcinoma. The 8th Hong Kong International Cancer Congress, 26-28 October 2001, Hong Kong.
73. Clinical trials in developing countries – unique trial opportunity. The 6th International Conference of Radiation Oncology, 31 January - 2 February 2001, Melbourne, Australia.
74. Management of nasopharyngeal carcinoma (Education Lecture). The 6th International Conference of Radiation Oncology, 31 January - 2 February 2001, Melbourne, Australia.
75. Nasopharyngeal carcinoma – controversies, re-treatment and new questions (Presidential Course). ASTRO 42nd Annual Meeting, 22-26 October 2000, Boston, U.S.A.
76. Re-treatment of nasopharyngeal carcinoma – controversies and challenges (Instructional Course). 2000 International and 6th National Head and Neck Cancer Congress, 12 June 2000, Shanghai, China.
77. Pamela Youde Nethersole Eastern Hospital experience with 6 fractions per week radiotherapy (Instructional Course). 2000 International and 6th National Head and Neck Cancer Congress, 7 June 2000, Hong Kong.
78. Management of nasopharyngeal carcinoma – lessons learnt and challenges ahead. Stanford University Medical Center, October 1999, Palo Alto, U.S.A.
79. Treatment of nasopharyngeal carcinoma: lessons learnt from the past and challenges for the future (Education Lecture). Annual Meeting for the European Society on Therapeutic Radiation Oncology, 21-24 September 1998, Edinburgh, U.K.
80. The new AJCC/UICC staging system for nasopharyngeal cancer. Head and Neck Cancer Congress, 7-13 June 1998, Hong Kong/Beijing, China.
81. Staging and prognostic factors in nasopharyngeal cancer: the Hong Kong experience. UICC Workshop on Nasopharyngeal Cancer, 11-14 February 1998, Singapore.
82. Nasopharyngeal cancer: effect of time dose fractionation on the therapeutic ratio. International Conference of Radiation Oncology, 5-7 June 1997, Beijing, China.
83. Radiotherapy of nasopharyngeal carcinoma. The 8th Overseas Meeting of the Royal College of Surgeons of Edinburgh Jointly with The College of Surgeons of Hong Kong, 27-30 October 1996, Hong Kong (read by Yau TK).
84. Role of radiotherapy in management of cervical metastases. The 3rd Hong Kong International Cancer Congress, 13-16 November 1996, Hong Kong.
85. Recurrent nasopharyngeal carcinoma revisited. The 2nd Hong Kong International Cancer Congress, 17-19 November 1995, Hong Kong.
86. Control of nasopharyngeal carcinoma by primary radiotherapy. Roentgen Centenary Congress and the 3rd Annual Scientific Meeting of Hong Kong College of Radiologists, 8-12 November 1995, Hong Kong.
87. Recurrent nasopharyngeal cancer: control and complications. Roentgen Centenary Congress and the 3rd Annual Scientific Meeting of Hong Kong College of Radiologists, 8-12 November 1995, Hong Kong.
88. Radiotherapy for nasopharyngeal carcinoma. The 2nd EORTC International Hong Kong Symposium on Current Trend in Cancer Care, 13 February 1995, Hong Kong.
89. Radiotherapy of head and neck: nasopharynx (Education Lecture). International Conference of Radiation Oncology, 21-25 June 1993, Kyoto, Japan.
90. Nasopharyngeal carcinoma: treatment results in Hong Kong. The 7th Asia-Oceanian Congress of Otorhinolaryngological Societies, 2-5 December 1991, Hong Kong.
91. Complications of radiation therapy. Hong Kong Symposium on Nasopharyngeal Carcinoma. Asian Oceanian Clinical Oncology Association, 22 April 1990, Hong Kong.

92. Late temporal lobe brain necrosis following radiation therapy of nasopharyngeal carcinoma. The 1st Shanghai International Conference on Radiation Oncology, 29 April 1987, Shanghai, China. Lee AWM, et al. (Plenary Lecture) delivered by Ho JHC).

National Conferences

1. Launching of Specialist Training for Clinical Oncology. 第九屆國家癌症中心學術年會暨第五屆深圳放射腫瘤學高峰論壇暨 2021 全國放療質控專家委員會會議, 18-19 December 2021, Online.
2. 港澳藥械通落地進展與真實世界研究情況. 第三屆粵港澳大灣區醫藥創新技術與市場准入高峰論壇, 18 December 2021, Online.
3. International oncology collaboration-Legacy. International Oncology Symposium on Advances in Radiation Oncology, the 5th Sanming Project Conference cum the 6th Multicenter Clinical Trials Design Training, 27-28 November 2021, China, Hybrid.
4. Pilot program on specialist training of clinical oncologists in Shenzhen (China). International Oncology Symposium on Advances in Radiation Oncology, the 5th Sanming Project Conference cum the 6th Multicenter Clinical Trials Design Training, 27-28 November 2021, China, Hybrid.
5. Adaptive treatment strategy for Nasopharynx Cancer. 第一屆鵬城國際智慧腫瘤學及精準放射治療高峰論壇暨 2021 年深圳市抗癌協會放療專業委員會年會, 北京大學深圳醫院, 26 November 2021, China.
6. Personalized Treatment Strategies for Nasopharyngeal Cancer. 廣東省臨床醫學學會鼻咽癌精準治療專業委員會第二次委員代表大會暨鼻咽癌前沿進展峰會, 12-13 November 2021, China, Online.
7. Launching of the Pilot Program on Specialist Training for Clinical Oncologists in Shenzhen. 廣東省醫師協會放射治療醫師分會學術年會暨第四屆粵港澳大灣區放射腫瘤醫師聯盟年會, 29-30 October 2021, China, Hybrid.
8. Locally Recurrent Nasopharyngeal Cancer: Management & Recommendations on Re-irradiation by Intensity Modulated Radiation Therapy. 2021 China International Exchange and Promotive Association for Medical and Health Care (CPAM) Nasopharyngeal Cancer Branch Inaugural Conference and Nasopharyngeal Cancer Minimally Invasive Surgery Training Course, 23-24 October 2021, Nanchang, China, Hybrid.
9. 探索引進港澳藥械通. 粵港澳大灣區生物醫藥創新高峰論壇, 16 October 2021, Guangzhou, China.
10. Suggestions for Reirradiation of Locally Recurrent Nasopharyngeal Carcinoma. 12th Shanghai International Conference on Radiation Oncology (SICRO XII), Fudan University Shanghai Cancer Center, 11-12 September 2021, Online.
11. 探索引進“粵港澳藥械通”, 第一屆粵港澳大灣區中醫藥高質量發展峰會暨生物醫藥與健康產業集群創新(橫琴)大會, 粵港澳中醫藥政策與技術研究中心, 9-11 September 2021, Zhuhai, China.

12. Global Advocacy to Eliminate Cervical Cancer. 中國抗癌協會世界癌症日科普活動, 30 January – 4 February 2021, online conference.
13. 鼻咽癌治療的過去、現在與未來. 廣東省臨床醫學學會鼻咽癌精準治療專業委員會成立大會暨鼻咽癌前沿進展峰會, 28-29 November 2020, Guangzhou, China.
14. Global Advocacy to Eliminate Cervical Cancer. Chinese Conference on Oncology, 12-15 November 2020, Guangzhou, China.
15. Chairperson and Discussion guest for the Cross-Strait Head And Neck Cancer Expert Forum, China Health Promotion Foundation / Taiwan Head and Neck Society, 29 August 2020, Online Conference.
16. The Establishment and the Achievements of the Hong Kong Nasopharyngeal Cancer Study Group 香港鼻咽癌臨床試驗的發展及成果. The 3rd Clinical Trial Workshop: Advance Cancer Medicine by Innovating Research with Clinical Patient Care. 6 June 2020, Shenzhen, China.
17. 局部復發鼻咽癌的優化管理. The 10th Chinese National Conference of Nasopharyngeal Cancer, 1-3 November 2019, Chengdu, China.
18. Fostering collaboration to achieve global unification in cancer staging. 2019 Chinese Conference on Oncology (CCO), 16-18 August 2019, Chongqing, China.
19. EBV-DNA for Nasopharyngeal Cancer Current Applications & Limitations. 11th Shanghai International Conference on Radiation Oncology, SICRO XI, 9-11 August 2019, Shanghai, China.
20. The Applications and Limitations of EBV-DNA for Nasopharyngeal Cancer. Annual Conference on Radiation Oncology, Guangdong Medical Association, 12 July 2019, Guangzhou, China.
21. 鼻咽癌臨床靶區(CTV)勾劃國際指南要點解讀, The 13th Pan-Pearl-River Area Congress of Radiation Oncology, 12-15 April 2018, Wuhan, Hubei, China.
22. Advances in Radiotherapy and Fundamental Standardization of Planning for Nasopharyngeal Cancer. The First International Particle Therapy and Clinical Research Summit (IPTCRS), 27-28 March 2018, Wuxi, China.
23. Pursuit of Excellence for Management of Nasopharyngeal Carcinoma (NPC). 2017 Annual Meeting of Taiwan Head and Neck Society, 9-11 June 2017, Taipei, Taiwan.
24. Long-Term Outcome for Concurrent-Adjuvant Chemotherapy for Advanced Nasopharyngeal Cancer. The 8th National Conference of Nasopharyngeal Cancer, 17-18 March, 2017, Shanghai, China.
25. Nasopharyngeal Cancer: Evolution in the management of nasopharyngeal carcinoma -2016 and beyond. The 5th Guangzhou International Symposium on Oncology, 1-2 December, 2016, Guangzhou, China.
26. 抗癌三部曲：戰勝腫瘤不是夢. 健康深圳大講堂. 2016年11月5日, 中國深圳.
27. Management of Nasopharyngeal Cancer – Evolving Technologies. The 13th National Conference on Radiation Oncology of CSTRO, 20-23 October, 2016, Chengdu, China.
28. Contribution by Hong Kong to the Battle against Nasopharyngeal Cancer. The 11th Pan-Pearl-River Area Conference of Radiation Oncology cum Prof. Ho Hung Chiu Memorial Symposium on Nasopharyngeal Cancer, 15-16 April, 2016; Shenzhen and Hong Kong, China.
29. Staging of Nasopharyngeal Carcinoma – Global Perspective. Chinese Society of Radiation Oncology, 30 October 2015, Chengdu, China.

30. Global Pattern on Nasopharyngeal Carcinoma – Correlation of Outcome with Access to Radiotherapy. The 10th Pan-Pearl-River Area Congress of Radiation Oncology, 16-19 April 2015, Guiyang, China.
31. Nasopharyngeal Cancer: Advances & Controversies in Chemoradiotherapy. The 7th Chinese National Nasopharyngeal Cancer Conference, 26-28 March 2015, Hangzhou, China.
32. Cancer Control in Hong Kong. The 9th Pan-Pearl-River Area Congress of Radiation Oncology, 17-20 April 2014, Chungqing, China.
33. Staging of Nasopharyngeal Cancer – Past, Present & Future. The 8th Pan-Pearl-River Area Congress of Radiation Oncology, 18-21 April 2013, Changsha, China.
34. UICC TNM Staging – Overall Perspectives and Collaboration to Improve Cancer Staging. National Conference of Esophageal Cancer, 15-17 December 2011, Guangzhou, China.
35. Neoadjuvant Chemotherapy for Nasopharyngeal Cancer. The 6th National Conference on Nasopharyngeal Cancer, 11-12 December 2010, Fuzhou, China.
36. Overview of Clinical Trials in Nasopharyngeal Cancer. The 5th National Conference on Nasopharyngeal Cancer, 31 July – 2 August 2009, Kunming, China.
37. Quality Management System and External Accreditation for Clinical Oncology Department. The 4th Pan-Pearl-River Area Congress of Radiation Oncology, 23-26 April 2009, Wuhan, China.
38. Multi-center Studies for Nasopharyngeal Cancer - Experience from Hong Kong Nasopharyngeal Cancer Study Group. The 3rd Pan-Pearl River Congress of Radiation Oncology, 23-24 Apr 2008, Fuzhou, China.
39. Advances in chemo-radiotherapy for nasopharyngeal carcinoma (Education Lecture). The 1st Pan-Pearl River Congress of Radiation Oncology, 12-14 May 2006, Guangzhou, China.
40. Altered fractionation for nasopharyngeal carcinoma. Seminar of continue education course on NPC radiotherapy, Department of Radiotherapy Cancer Centre, Sun Yat-Sen University, 9-10 November 2004, Guangzhou, China.

Local Conferences

1. Panel Discussion for title “Innovation in personalised healthcare: Important advances are being made, how can we all benefit?”, French Chamber of Commerce and Industry in Hong Kong, 24 February 2022, Online.
2. Screening for NPC in the relatives of NPC patients. NPC Screening Conference “Recent Advances in Screening and Early Detection of Nasopharyngeal Carcinoma: Is it Time to Act?”, The Chinese University of Hong Kong, 4-6 November 2021, Online.
3. Evolution of Radiotherapy & Treatment of Nasopharyngeal Cancer. 22nd Meeting of Medical History Interest Group, Hong Kong Museum of Medical Sciences Society, 25th Anniversary Medical Education Series, 23 October 2021, Hybrid.
4. 大灣區醫療發展的特有機遇 - 香港大學深圳醫院的分享. 香港醫療界融入大灣區的機遇和挑戰, 香港中華醫學會, 4 September 2021, Hybrid Medical Forum.
5. Collaboration in Oncology Care under the Greater Bay Area Framework. American Chamber of Hong Kong Event, 2 June 2021, Virtual Platform.
6. My Journey in Women for Oncology. Inaugural Ceremony cum Scientific Meeting of the Hong Kong Women for Oncology (HKW4O), 6 November 2020, Hong Kong.

7. Pursuit of Excellence in Oncology Research-Progress in Therapeutics for Nasopharyngeal Carcinoma (NPC). ACRP Oncology Research Symposium, 1 April 2017, Hong Kong.
8. Nasopharyngeal Cancer in Hong Kong over previous 60 years. The 3rd Hong Kong International Oncology Symposium, 28–30 October 2016, Hong Kong.
9. Nasopharyngeal Carcinoma. Gordon Research Conference, Hong Kong, 26 June – 1 July 2016.
10. Clinical Trials of Head & Neck Cancer in Hong Kong – Past Achievements and Future Prospects. The Hong Kong Head & Neck Society, 15 October 2015, Hong Kong.
11. Contouring Course on IMRT for Nasopharyngeal Cancer. Hong Kong Nasopharyngeal Cancer Symposium, 23-24 August 2014, Hong Kong.
12. Nasopharyngeal Cancer: Controversy in Chemoradiotherapy. Hong Kong Nasopharyngeal Cancer Symposium, 23-24 August 2014, Hong Kong.
13. Nasopharyngeal cancer – Controversies about the best sequence for combining radiotherapy and chemotherapy. The 20th Annual Scientific Meeting, Hong Kong College of Radiologists, 27-28 October 2012, Hong Kong.
14. Unique Challenges in the Battle against Nasopharyngeal Cancer. Hong Kong Medical Council, 15 September 2011, Hong Kong.
15. Overview of Collaborative Trials in Hong Kong focusing on Nasopharyngeal Cancer. Hong Kong Head and Neck Society, 13 November 2008, Hong Kong.
16. Advances in the Management of Nasopharyngeal Cancer. Annual Scientific Symposium 2008, St. Teresa's Hospital Cancer Centre, 9 March 2008, Hong Kong.
17. Current Standard of Care for Different Stages of Nasopharyngeal Carcinoma. Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, 13 June 2007, Hong Kong.
18. Efficacy of Chemoradiation for Nasopharyngeal Carcinoma. Head and Neck Course 2007, Department of Surgery, The University of Hong Kong Medical Centre, 7 June 2007, Hong Kong.
19. Overview of Studies by the Hong Kong Nasopharyngeal Cancer Study Group. Hong Kong Head and Neck Society, 28 September 2006, Hong Kong.
20. Chemoradiation for NPC. The 12th Annual Scientific Meeting, Hong Kong College of Radiologists, 30-31 October 2004, Hong Kong.
21. Induction chemotherapy with Cisplatin-Gemcitabine and concurrent accelerated chemo-RT for advanced nasopharyngeal carcinoma. Hong Kong Nasopharyngeal Cancer Study Group, 9 December 2003, Hong Kong.
22. Oncology services for orthopedic problems. Association of Private Orthopedic Surgeons, 22 June 2000, Hong Kong.
23. Treatment of recurrent nasopharyngeal carcinoma – controversies and uncertainties. The Chinese University of Hong Kong, December 1998, Hong Kong.
24. Nasopharyngeal carcinoma: local control by megavoltage irradiation. The 2nd Annual Scientific Meeting of Hong Kong College of Radiologists, 26 June 1994, Hong Kong.
25. Nasopharyngeal carcinoma: survival after local recurrence. The 1st Scientific Meeting by Hong Kong Head and Neck Society, 4 March 1993, Hong Kong.
26. Temporal lobe necrosis following radiation therapy for nasopharyngeal carcinoma. The 8th Asian Conference for Radiographers and Radiation Technologists, 10-13 October 1991, Hong Kong.